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Malaria is the most important vector-borne disease mainly affecting sub-Saharan 
Africa. Malaria, like tuberculosis, is curable but the disease is most prevalent in 
populations, which cannot afford modern pharmaceuticals. The malaria parasite has 
developed resistance to most antimalarial drugs. Medicinal plants have been used 
since ancient times to treat a variety of diseases. Traditional healers are more common 
in developing countries than medical doctors and more than 50% of the South African 
population consults traditional healers. The aim of this study was to investigate two 
medicinal plants Siphonochilus aethiopicus (Zingiberaceae) and Aloe ferox 
(Asphodelaceae) for their antimalarial properties and to isolate and characterize novel 
antiplasmodial compounds. Preliminary bioavailability studies of a novel 
furanoterpenoid isolated from S. aethiopicus were performed. 
 
The ethyl acetate extract of S. aethiopicus was active in vitro against both chloroquine 
(CQ) sensitive D10 and CQ resistant K1 strains of P. falciparum with IC50-values of 
2.9 µg/ml and 1.4 µg/ml, respectively. This extract was subjected to bioassay-guided 
fractionation which yielded three novel structurally-related furanoterpenoids. Nuclear 
magnetic resonance (1D and 2D) and mass spectrometry was used to determine the 
chemical structure of compounds. The most active furanoterpenoid (C15H16O3) 
showed similar in vitro antipla modial activity to the ethyl acetate extract. No in vitro 
cytotoxicity was observed with the ethyl acetate extract as well as the isolated 
compounds against the Chinese Hamster Ovarian cell-line. The ethyl acetate extract 
and compounds isolated were more active in vitro against the CQ resistant strain of 
the parasite compared to the CQ sensitive strain. In vivo testing was performed using 
a murine malaria model. The ethyl acetate extract of S. aethiopicus was more active in 
vivo than the most active compound using a 4-day suppressive test and showed no 
toxicity. The in vivo schizontocidal activity of the S. aethiopicus extract was further 
investigated in a 7-day suppressive test using two drug formulations; an aqueous-
based 5% sodium bicarbonate (with addition of 5% ethanol) and lipid-based 
formulation. The 5% sodium bicarbonate formulation resulted in a suppression of 
parasitemia while the lipid-based formulation did not suppress parasitemia. Further in 











moderate prophylactic effect was observed. Drug formulation and route of 
administration have an effect on pharmacokinetic factors such as bioavailability and 
rate of metabolism resulting in either increased or decreased in vivo schizontocidal 
activity. The active compound might be metabolized to an inactive component or be 
poorly absorbed. An in vivo mouse-model was developed to investigate 
pharmacokinetic parameters. Bioavailability studies of the most active compound 
showed that formulation and route of administration have an effect on drug 
absorption. Thus in vivo schizontocidal activity might be improved if given in optimal 
formulation and route of administration. The absorption of the active component was 
improved when administered as a crude extract as opposed to a single entity. A 
preliminary in vivo metabolism study could not identify the metabolites of the active 
compound. The pharmacokinetic study suggests that the lack of in vivo schizontocidal 
activity of the active furanoterpenoid is due to poor absorption rather than rapid 
metabolism. 
 
The dichloromethane extract of A. ferox whole leaf collected in winter were more 
active in vitro against P. falciparum than the summer collections. The whole leaf 
extracts showed greater antiplasmodial activity than the inner gel and outer leaf 
separated. Four compounds were isolated from the whole leaf extract and outer leaf 
extract through bioassay-guided fractionation. Two known compounds were isolated 
namely aloe-emodin and aloesin as well as two unknown compounds. The most active 
compound was moderately active against the CQ sensitive strain of P. falciparum 
with an IC50-value of 2.9 µg/ml. The exact chemical structure could not be 
determined. The other three compounds were not active in vitro. The investigation of 
whole leaf dichloromethane extract of A. ferox for in vivo schizontocidal activity 
revealed greater suppression of parasitemia against the CQ resistant strain than the 
CQ sensitive strain of the parasite. No toxicity was observed with the crude extract 
during in vitro or in vivo testing. Different components in A. ferox might play a role in 
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MRM Multi reaction monitoring 
MS Mass spectrometer 
MTT 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
NAD Nicotinamide adenine dinucleotide 
NBT Nitro blue tetrazolium 
ND Not determined 
NHLS National Health Laboratory Service 
NMR Nuclear magnetic resonance 
NOESY Nuclear Overhauser enhancement and exchange spectroscopy 
PBS Phosphate buffered saline 
PE Petroleum ether 
P-gp P-glycoprotein 
pLDH Parasite lactate dehydrogenase  
pRBC Parasitized red blood cells 
PTLC Preparative thin layer chromatography 
PYR Pyrimethamine 
Q1 Quadrupole 1 
Q3 Quadrupole 3 
Q-TOF Time of flight mass spectrometer 
RBC Red blood cell 
RI Resistance index 
RP Reverse phase 
SB Sodium bicarbonate 
SC Subcutaneous 
SD Standard deviation 
SDA Sabouraud dextrose agar 
SFD Sulfadoxine 
SI Selectivity index 
SMEDDS Self microemulsifying drug delivery system 
SPE Solid phase extraction 
TB Tuberculosis 
TLC Thin layer chromatography 
TM Traditional medicine 
TNF Tumour necrosis factor 
TSA Tryptone soya agar 
TSB Tryptone soya broth 
UV Ultraviolet 

































































1.1 History of malaria 
 
Malaria is an ancient disease still affecting modern society. Records of malaria 
incidences date back to 6000 years in Egypt and China and 1600 BC in India (WHO, 
1986).  The Ancient Greeks and Romans have made the association between fevers 
and stagnant waters and swamps (Konradsen et al., 2004). Soon after the discovery of 
mosquitoes as the vectors of malaria various interventions were implemented to 
eradicate this disease. Kerosene oil was applied to potential breeding sites but this had 
a limited effect due to the oil evaporating in the warm climate. Canals, swamps and 
other potential breeding sites were also drained. A lack of knowledge in ecology and 
epidemiology limited the success of these methods. A global initiative to eradicate 
and control malaria by the WHO succeeded in Europe and Northern America (WHO, 
2005). The emergence of drug-resistance and lack of political and financial support 
prevented the same success rate in poorer countries. Collaborations between different 
disciplines of science and also with communities are vital for the success of 
interventions to effectively control malaria.  
 



















Malaria is responsible for more than one million deaths and almost 500 million 
clinical cases per year (WHO, 2005). Malaria is generally endemic in the tropics 
extending into the subtropics which include Africa, India, Brazil, Sri-lanka, Thailand, 
Indonesia, Vietnam, Cambodia, the Middle East and China (WHO, 1999). 
Approximately 40% of the world’s population live in malaria risk areas (Fig 1). More 
than 80% of malaria deaths occur in sub-Saharan Africa and children under the age of 
five are the most affected. The World Health Organisation (WHO) estimates that 10 
000 women and 200 000 infants die annually as a result of malaria infection during 
pregnancy (WHO, 2007). People in Africa living in malaria risk areas develop at least 
one clinical attack per year and according to statistics there is one malaria death every 
30 seconds (Greenwood et al., 2002 and Winstanley et al., 2002).  
 
Global warming and travelling have contributed to the spread of malaria. Malaria can 
be effectively treated but is most prevalent in poorer populations. Nearly 250 times 
more malaria deaths occur in the poorest countries compared to the richest. Malaria-
endemic countries carry great social and economic burdens but more importantly a 
high cost of human lives. According to the WHO malaria contributes synergistically 
with HIV/AIDS to morbidity and mortality in areas highly affected by both infections 
(WHO, 2007). Malaria vector control includes indoor residual spraying of long-acting 
insecticides and long-lasting insecticidal nets. Antimalarial treatment policies vary 
between countries and depend on the epidemiology of the disease, transmission, drug 
resistance and political and economical influence. The staggering statistics associated 
with this disease has lead to initiatives by global organisations to combat malaria. 
Despite valiant initiatives by the Global Fund, the Gates Foundation and the WHO the 
burden of malaria on poor countries is still high (WHO, 2005). The effective 
prevention and treatment of malaria is estimated at $3.2 billion per year but only a 




















1.3 Impact of malaria in South Africa  
 
Malaria risk areas in South Africa include Kwazulu-Natal, Mpumalanga and the 
Northern Province according to the Malaria in South Africa database (2003). Malaria 
cases in Kwazulu-Natal have decreased to less than 3 500 for the 2001-2002 malaria 
season from over 40 000 for the 1999-2000 season. This is thought to be partly a 
result of re-introducing the spraying of DDT to control the vector, changing the first-
line treatment to co-artemether in some areas, and applying a regional approach to 
malaria control as part of the Lubombo Spatial Development Initiative, which covers 
eastern Swaziland, southern Mozambique and north-eastern Kwazulu-Natal.  
 
1.4 Malaria parasite and vector 
 
A military doctor, Charles Laveran, first discovered the malaria parasite in 1880 and 
was awarded the Nobel Prize in 1907 for this discovery (CDC, 2004). Malaria is 
caused by the Plasmodium genus of protozoan parasites, namely Plasmodium 
falciparum, P. vivax, P. ovale, and P. malariae (WHO, 2001). The Plasmodium 
species; with the exception of P. malariae (may affect the higher primates) are 
exclusively parasites of man. P. falciparum is the most common protozoan in Africa 
(WHO, 2005). The puzzle of malaria transmission was solved by Ronald Ross in 
1897 by identifying the Anopheline mosquito as the malaria vector (CDC, 2004). He 
consequently also received the Nobel Prize in 1902. Only female mosquitoes transmit 
malaria as they need a blood meal to produce eggs (Moorthy et al., 2004). The life 
cycle of the parasite is divided between a vertebrate human host and an insect vector. 

















Figure 2 Life cycle of the malaria parasite (WHO, 2001) 
 
Two asexual stages namely exo-erythrocytic and intra-erythrocytic occur in the 
human host. The exo-erythrocytic stage occurs in the liver and is asymptomatic. If an 
infected mosquito takes a blood meal from a human it releases a small amount of 
saliva which contains an anticoagulant and sporozoites into the bloodstream. Once in 
the bloodstream sporozoites penetrate the liver cells. Sporozoites mature to 
merozoites which are released from infected liver cells. Merozoites either invade 
other liver cells or infect erythrocytes. The intra-erythrocytic stage occurs in 
erythrocytes and is symptomatic. Merozoites enter erythrocytes where it undergoes 
asexual replication to produce schizonts. Mature schizonts rapture and merozoites are 
released from infected erythrocytes into the bloodstream. This intra-erythrocytic cycle 
is repeated every 48 or 72 hours depending on the Plasmodium spp. Merozoites can 
also develop into male or female gametocytes. These gametocytes can be ingested by 
a mosquito during a blood meal and fuse inside the mid-gut of the vector. Sexual and 














migrate to the salivary glands of the mosquito where they can infect a human host. 
The main focus of this study will be on the intra-erythrocytic stage of the life cycle.  
 
Several tissues and organs are affected by severe malaria (Miller et al., 2002). The 
surface of infected red blood cells is modified making it able to adhere to small blood 
vessels which lead to an obstruction to tissue perfusion. Adhesion of the parasite to 
endothelium protects it from destruction in the spleen. A principle pathophysiological 
feature of severe malaria is metabolic acidosis. There are long-term disability risks 
associated with severe malaria (Winstanley et al., 2002). In pregnancy malaria can 
cause severe anaemia, low birth weight and an overall low survival rate of the foetus. 
Cerebral malaria is associated with metabolic acidosis and elevated plasma creatinine 
levels (Oguche et al., 2002). Other symptoms of malaria include fever, chills, shaking, 
flu-like symptoms, muscle aches, tiredness, and headache (CDC, 2000). Nausea, 
vomiting, and diarrhoea may also occur. Malaria may cause anaemia and jaundice 
because of the loss of red blood cells. An infection with P. falciparum, if not promptly 
treated, may cause kidney failure, seizures, mental confusion, coma and death.  
  
1.5 Malaria research 
 
Research on the biology of the malaria parasite has greatly contributed to the 
successful development of screening assays and potential vaccines. The development 
of effective antimalarial treatments has been hindered by the parasite’s complex life 
cycle and extensive polymorphisms in its genome. The malaria parasites use red 
blood cells to acquire haemoglobin which is used as a source of amino acids needed 
for parasite growth. Haemoglobin is hydrolysed by protease enzymes in the parasite’s 
food vacuole to form the globin (protein) and heme (Baelmans et al., 2000). Heme is 
toxic to the parasites and is detoxified or removed (Orjih et al., 1981). During this 
process the parasite produces a potential toxin, ferriprotoporphyrin. The parasite 
forms an insoluble polymer hemazoin, also known as the malaria pigment which 
detoxifies ferriprotoporphyrin. This process is a potential drug target as a compound 
that inhibits the polymerisation of haematin will be lethal to the parasite. Hemozoin 
formation may occur spontaneously in the acidic food vacuole of the parasite (Dorn et 














assay to detect compounds inhibiting β-hematin formation was developed (Bohle et 
al., 1997; Egan et al., 1999 and Ncokazi et al., 2005). The conventional methods for 
determining parasitemia have been replaced by different types of in vitro assays. 
Early methods for activity testing were mainly using avian malaria models and 
monkeys (Phillipson et al., 2001). These methods were time-consuming and not 
suitable for bioassay-guided fractionation. The oldest method of detection was 
developed by Desjardins et al. (1979) and was based on the incorporation of tritium-
labelled hypoxanthine. The lactate dehydrogenase enzyme of P. falciparum is 
essential for energy production of the parasite. The parasite lactate dehydrogenase 
(pLDH) assay has proven successful as a method to determine parasite viability 
(Makler et al., 1993 and Basco et al., 1995). A monoclonal antibody-bound 
immunocapture assay of pLDH has been developed to combat the influence of colour 
with crude herbal extracts in the standard pLDH assay (Xu et al., 2007). DNA-based 
antimalarial assays using fluorescence dye has also been developed (Smeijsters et al., 
1996).  
 
The recent sequencing of the genomes of P. falciparum and A. gambiae has cleared 
the way for developing new drug and vaccine targets (de Roode et al., 2003). 
Advances in technology have assisted in the creation of transgenic mosquitoes which 
do not transmit malaria (Ito et al., 2002). This has lead to concerns about the effect of 
these transgenic mosquitoes on humans and the environment as well as the possible 
evolution of the parasite. Attempts to develop a vaccine have been hindered by the 
parasite’s complex l fe cycle. Protozoa, unlike pathogenic bacteria, share many 
biochemical pathways with their human host. Early attempts at vaccination included 
literally being bitten by about a thousand malaria-infected mosquitoes that had been X 
irradiated. The genomes of P. falciparum and A. gambiae have identified 
approximately 5300 P. falciparum antigens. Genetic vaccination with plasmid-DNA 
expression encodes for a relevant antigen without using live agents (Martin et al., 
1999). DNA vaccines have proven to be safe, well-tolerated and immunogenic 
(Parker et al., 1999 and Wang et al., 1998). A vaccine based on plasmid-DNA has 
advanced to clinical trials (Martin et al., 1999). Vaccine development against malaria 
is still under investigation. With all this information and technologies in hand, the 














1.6 Background of traditional medicine 
 
Ancient civilisation recorded the use of traditional medicine for the treatment of 
malaria and more than 1 000 plant species are used to treat fevers and malaria (WHO, 
1986 and Willcox et al., 2001). Traditional medicine is cheap and easily available in 
developing countries. Traditional healers are more common in developing countries 
than medical doctors. Religion and culture are important as the use of a medicinal 
plant usually accompanies some sort of ritual. Parasite-resistance to whole-plant 
extracts has not been reported which might be due to the synergistic effect of various 
compounds within a whole-plant extract (Phillipson et al., 1991 and Willcox et al., 
2000). Phytotheraphy may have fewer side effects due to many active compounds 
working together and administered at smaller doses. Whole-plant extracts are still 
used as an alternative antimalarial treatment especially in developing countries. Two 
of the most potent antimalarial agents in history namely quinine and artemisinin were 
isolated from medicinal plants. It is estimated that 50% of prescription drugs originate 
from natural products (Edinburg et al., 1998). 
 
Most traditional medicine (TM) is given orally but some plant extracts are given 
rectally, topically applied or inhaled (Edinburg et al., 1998).  Although parenteral 
administration is not widely used, some medicinal plants are placed in a small incision 
in the skin to enhance the effect. Several factors influence the determination of a dose, 
such as size, age, constitution and severity of the disease. Measurements are often 
approximate in the absence of scales or measuring containers. Most traditional 
medicines are freshly prepared. Lipophilic compounds like artemisinin can be 
administered at lower doses in an aqueous infusion (Phillipson 1991). With aqueous 
preparations lower toxicity and synergism of different compounds can be observed. 
Studies have shown the potential harm of combining standard antimalarials with TM 
(Ekong et al., 1991 and Kirby et al., 1995a). Combinations can lead to sub-therapeutic 
exposure of the drug to the parasite which can aid in the development of drug-
resistance. However not all combinations of chloroquine and TM’s are antagonistic 
(Muregi et al., 2003). Some medicinal plants can exert activity which might not be 
primarily antiprotozoal but might address the symptoms associated with malaria. 
Many populations living in malaria-risk areas acquire natural immunity. Medicinal 














immunity (Kirby et al., 1996). Health care systems in most developing countries are 
not satisfactory. Poverty, lack of expertise and political instability further increase the 
dependence of communities on cheap and accessible indigenous medicine. The more 
primitive plants are used as foods while the more evolved species are used as 
medicine (Hedberg et al., 1993). There are more plants reported for medicinal use 
than reported as foods.  Most plants have evolved secondary metabolites as a defence 
mechanism against mammals and insects. The Food and Drug Association has 
classified herbal substances as dietary supplements under the Dietary Supplement and 
Health Act of 1994 (Marcus and Grollman et al., 2002). This has contributed to a lack 
of control in this field.  
 
A single active constituent cannot always replace the whole plant extract. A. annua 
contains a plethora of compounds including artemisinin (Phillipson et al., 2001). The 
blood red sap from the South American Croton sp. is traditionally used to treat 
wounds and is commonly known as ‘Dragons blood’. This natural product has been 
investigated for its traditional uses and the constituents were found to work 
synergistically in wound healing. Clinical studies with a herbal mixture of ten plants 
showed that all ten herbs are needed for clinical effectiveness. A multi-disciplinary 
approach is needed to honour the full potential of TM. The majority of populations in 
developing countries rely on TM. Science has evolved and continues to build on 
current technologies. The clinical evaluation of TM for quality, safety and efficacy 
can be achieved using acceptable protocols. To date we have only dented the surface 
of biodiversity as the vast majority of the world’s medicinal plants have not been 
investigated for biological activity. Tropical rain-forests are under threat and with it 
the annihilation of hundreds of plant species (Phillipson et al., 1994). An estimated 
25% of all plant species will be extinct by the mid-21st century. The scientific 
investigation of our natural resources might lead to the discovery of novel 
antiplasmodial compounds. 
 
1.7 Traditional medicine in South Africa 
 
The indigenous knowledge of South Africa date back to 1 000 BC which is long 














(Edinburg et al., 1998). Southern Africa has more than 30 000 species of higher plants 
which makes it a biodiversity hot spot (Van Wyk et al., 1997). The Cape Floral 
Kingdom alone has almost 9 000 plant species making this region the most diverse 
temperate floral kingdom on earth, rivalling the tropical rainforests in terms of species 
richness. South Africa has a remarkable biodiversity and cultural diversity with 
approximately 3 000 species of medicinal plants. There are approximately 200 000 
traditional healers in South Africa, and more than 50% of the South African 
population consult these healers, usually in addition to using modern biomedical 
services. Nearly 400 species of indigenous plants are sold commercially as TM in 
Kwazulu-Natal, South Africa (Kubukeli et al., 1999). The value of an ethnobotanical 
approach to drug discovery was demonstrated with antiplasmodial studies on South 
African medicinal plants which yielded several promising plant extracts (Prozesky et 
al., 2001 and Clarkson et al., 2004).  Traditional healers can be potential partners in 
the delivery of primary health care. The WHO defines health as a complete state of 
physical, social and mental well-being and the practice of traditional healers who 
examine the whole being (physical, mental and spiritual) is in line with this definition. 
African traditional healing practices vary between countries depending on social and 
cultural heritage and traditions. Although South Africa has such a rich plant resource, 
very little antimalarial work has been done on South African plants. This is probably 
due to the lack of malaria incidences in South Africa which makes the search for 
medicinal plants used as antimalarial treatment difficult. 
 
1.8 Drug discovery and development 
 
Conventional drug development takes at least ten years and the cost associated with 
drug discovery and development is estimated at $800 million per drug entity reaching 
the market (Shearer et al., 2005). Several steps are involved in getting a potential drug 
from a test tube to human subjects. The common processes in drug discovery are 

















Scheme 1 Drug discovery process 
 
During the 1975-1996 period, 1 223 new drugs were developed and only three were 
antimalarial drugs. Plasmodium is one of the most researched causative organisms 
especially in the field of plant medicine (Phillipson et al., 2001). Antimalarial 
compounds must be selective towards the parasite without harming the human host. 
Plants have an advantage from millennia of evolution to create a rich source of 
chemically diverse compounds. Ironically the chemical diversity and novelty of 
natural products is also a disadvantage as supply and access often discourage research 
sponsored by pharmaceutical companies (Phillipson et al., 1991). Chemical synthesis 
of natural products can be complex and often economically unviable. Pharmaceutical 
companies are looking towards combinatorial chemistry and high throughput 
screening for drug development (Eddershaw et al., 1999). However the development 
of large libraries of compounds has not delivered the expected results (Hedberg et al., 
1993). Lipinski’s ‘Rule of 5’ serves as a drug-design guideline which can aid in 
absorption (Lipinski et al., 1997). This rule limits the design of compounds but its 
usefulness in predicting well-absorbed molecules is noteworthy. Natural products 
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developing synthetic and semisynthetic compounds (Mueller et al., 2000).  Structure 
activity relationships have contributed significantly in antimalarial drug development 
(Tagboto et al., 2001). 
 
The discovery of the antimalarial drug artemisinin by the Chinese focused the 
attention of antimalarial drug development back to medicinal plants (Mueller et al., 
2000). Currently there are no effective alternatives to artemisinin in the treatment of 
P. falciparum malaria on the market or in the late stages of drug development (WHO, 
2007). Tang et al. (2006) encourage an efficacy driven approach to investigate 
traditional Chinese medicine. This evidence-based approach proposes the study of 
TM already in use. Throughout history medical interventions such as penicillin and 
the smallpox vaccine were implemented without the knowledge of mechanism of 
action. Clinical evaluation of TM requires a combination of methodologies. The 
outcome or benefits of a clinical trial must be clearly defined. The investigation of 
herbal formulations such as Changshan (Dichroa febrifua) showed that a single active 
approach to drug discovery is not always viable (Willcox et al., 2004a). Changshan 
studies highlight that false negatives, using this approach with regard to TM research, 
can occur as some plants only work in combination. Several success stories of a 
ethonobotanical or phytochemical approach to drug discovery include morphine from 
the opium poppy, tubocurarine (Chondrodendron tomentosum), vinblastine and 
vincristine (Catharanthus roseas) and taxol (Taxus brevifolia) (Phillipson et al., 
1994). These compounds among several other natural products serve as template 
molecules for synthetic analogues. Advances in plant biotechnology have improved 
the understanding of biosynthetic pathways and enzymes involved in the production 
of active constituents. Plant cell cultivation has been successfully used to produce 
higher concentrations of active components (Choi et al., 1999). Substances of 
pharmaceutical interest such as taxol are produced using biotechnological processes 
involving the cultivation of bacteria, yeast, plant or mammalian cells. The 
ethnobotanical approach to drug discovery is less expensive in terms of technology 
than the highly technological approaches (Kirby et al., 1996). 
 
The process of TM investigation must take into account the intended route of 














evaluation of lead compounds includes absorption, distribution, metabolism and 
excretion (ADME) (Shearer et al., 2005). Drug metabolising enzymes play an 
important role in the development of lead compounds. Virtual ADME studies can be 
conducted without putting on a laboratory coat. Drug interactions are clinically 
important and are influenced by drug-, patient- and administration-related factors 
(Dresser et al., 2000). Interactions leading to higher plasma concentrations can 
enhance adverse effects and / or efficacy. The CYP enzymes are responsible for phase 
I hepatic metabolism of a broad spectrum of therapeutic drugs. The system for 
metabolising compounds and the means of analysing the metabolic reaction is very 
important. The ideal is to mimic exactly the in vivo situation through comprehensive 
in vitro screens. Cytochrome P450 (CYP) enzymes and human and liver microsomes 
are routinely used for in vitro metabolism studies. In vitro screens unlike in vivo 
screens require less material, they are cost effective and there are no ethical 
controversies. In vitro systems using Caco-2 cell-lines have been developed to predict 
possible drug absorption by the small intestine epithelium (Hilgers et al., 1990). CYP 
3A4 is one of the most important human enzymes responsible for the 
biotransformation of 60% of oxidised drugs (Dresser et al., 2000). Novel methods for 
in vivo evaluation of specific enzymes such as CYP 3A4 have been developed 
(Granvil et al., 2003).  Pharmacokinetic properties of a potential drug should be 
evaluated early during preclinical drug development. Although great progress has 
been made in the field of in vitro metabolism it still cannot simulate the complexicity 
of an in vivo system. There is a need to develop rapid, cost-effective and ‘animal 
friendly’ methods to evaluate in vivo metabolism.  
 
Advances in analytical techniques have revolutionised medicinal plant research 
(Phillipson et al., 2003). Powerful techniques such as high performance liquid 
chromatography, mass spectrometry and nuclear magnetic resonance (NMR) have had 
a phenomenal effect on phytochemical research. Hyphenated bioanalytical techniques 
such as NMR-solid phase extraction have enabled rapid identification of known and 
unknown compounds irrespective of their concentration in medicinal plants (Clarkson 
et al., 2006). Despite all these advances in technology the majority of plants are yet to 














Therefore the scientific investigation of traditional medicine to prove efficacy and 
safety will be of great benefit to these communities.  
 
1.9 Natural products and antimalarial chemotherapy 
 
Plasmodium has developed resistance to most antimalarial drugs and the mosquito 
vector has developed insecticide-resistance (Moorthy et al., 2004). Haemoglobin 
breakdown is necessary for the action of chloroquine (CQ) and artemisinin (Peters et 
al., 1986). Understanding the mechanism of action of a drug aids in understanding the 




1.9.1.1 History of Cinchona 
 
The Cinchona (Rubiaceae) bark discovered in Peru in the early 17th century is known 
as one of the oldest remedies for malaria (Willcox et al., 2004a). This genus is 
indigenous to South America. People with different backgrounds from royalty to 
common workers used the plant throughout history but its discovery is still debated 
today.  Great secrecy surrounded this traditional medicine which resulted in the loss 
of information concerning its traditional preparation. The most important Cinchona 
spp. for pharmaceutical and commercial purposes are C. ledgeriana, C. succirubra 
and C. officinalis.  
 
1.9.1.2 Quinine-based antimalarials 
 
Two alkaloids cinchonine and quinine were isolated from the Cinchona bark in the 
early 19th century. This was a major breakthrough and later resulted in the formulation 
of synthetic antimalarials such as amodiaquine, CQ and mefloquine which is based on 
quinine. A further 30 alkaloids were isolated from the bark but the most potent in 















































Figure 3 Chemical structures of the quinoline-based antimalarials 
 
Quinine was discovered in a time when the world was in desperate need for 
antimalarial drugs and the fact that these compounds originated from traditional 
medicine already in use outweighed the risk of no treatment. Several clinical trials on 
Cinchona and its alkaloids were conducted in the early 20th century (Waters et al., 
1916; Acton et al., 1920 and Hicks et al., 1935). The pharmacokinetics and 
mechanism of action of Cinchona alkaloids were studied decades after it was first 
clinically used. The Cinchona bark and its alkaloids especially quinine were 
extensively investigated. Studies suggested that the crude extract is as effective as 
quinine. Quinine and quinidine have good oral bioavailability (White et al., 1996). 
Side-effects associated with Cinchona alkaloids include hearing impairment, nausea 
and visual disturbances (Karbwang et al., 1993 and White et al., 1981). Fletcher et al. 
(1934) also stated that the “bitter taste is enough to make healthy people vomit, let 

















The difficulties encountered with antimalarial vaccines have resulted in scientists re-
evaluating current antimalarial drugs such as CQ. Cerebral malaria is associated with 
over-stimulation of the immune system and cytokine network in particular tumour 
necrosis factor (TNF) and interleukin-6 (IL-6) (Kwiatkowski et al., 1990; Picot et al., 
1990 and Aderka et al., 1989). Picot and co-workers (1993) showed that CQ inhibits 
the secretion of TNF and IL-6. TNF inhibition was caused by disrupting normal iron 
metabolism. The inhibition of cytokine secretion in the pathophysiology of cerebral 
malaria can enhance patient survival without having a direct effect on the parasitemia. 
CQ might be useful as a prophylactic agent in cerebral malaria.    
 
Synergism observed with different components might be an effective treatment 
against the quinine-resistant parasite. A recent study showed that the combination of 
chloroquine and certain plant extracts leads to a synergistic effect against multi-drug 
resistant P. falciparum (Muregi et al., 2003). The combination of quinine with 
quinidine and cinchonine was more effective against the quinine-resistant parasites 
and even a mixture of alkaloids was more effective than a single compound (Druihle 
et al., 1988). A combination of alkaloids was as effective as quinine and fewer side-
effects were also observed (Bunnag et al., 1989). In this modern age the Cinchona 
bark is still being used to treat malaria in several countries. The legacy of Cinchona 
specifically its contribution to antimalarials has greatly benefited the human race. 
 
1.9.1.3 Mechanism of action and resistance 
 
This class of antimalarial drugs act by binding to free heme thus preventing the 
conversion to non-toxic hemazoin. Quinoline antimalarials accumulate in the acidic 
food vacuole of the parasite which is partly due to its basic nature. CQ accumulation 
is much less in resistant strains than in sensitive strains of the parasite. Early studies 
showed that the efflux of CQ is 40-50 times more with chloroquine-resistant (CQR) 
strains than chloroquine-sensitive (CQS) strains of P. falciparum (Krogstad et al., 
1987). Resistance might be due to a decrease in the influx of CQ or an increase in the 
efflux of CQ or a reduction in the binding affinity of the drug to its target molecule. 
These hypotheses have been extensively investigated over the years. CQ was 














et al., 2004b). Increasing levels of drug-resistance has resulted in a change of first-line 
treatment for malaria. Mefloquine (MQ) has been used to treat CQR malaria. 
Unfortunately resistance to MQ has evolved over recent years. P-glycoprotein (P-gp) 
is an ATP-binding molecule located on the plasma membrane of the cell and has been 
linked to the development of resistance in cancer (Grossi et al., 2004). A P-gp 
homologue (Pgh-1) is located on the food vacuole of P. falciparum (Cowman et al., 
1991). P. falciparum multidrug-resistant (pfmdr-1) gene is known as the gene 
encoding Pgh-1 and is amplified in CQR strains of P. falciparum. Additionally 
mutations in Pgh-1 have been associated with CQR parasites (Reed et al., 2000). Pgh-
1 can serve as an efflux pump which may lead to reduced drug concentrations in the 
food vacuole. MQ-resistance is also associated with an increase in pfmdr-1 gene 
expression (Price et al., 2004). The antidepressant fluoxetine is a P-gp inhibitor and 
has shown to enhance the susceptibility of resistant P. falciparum to CQ (Coutaux et 
al., 1994 and Singh et al., 2000). Further studies showed that fluoxetine potentiates 
the effect of CQ and MQ on multidrug-resistant P. falciparum (Khairul et al., 2006).  
 
Antihistaminic compounds have demonstrated CQ resistance reversal properties 
against in vitro and in vivo strains of Plasmodium (Peters et al., 1990). Several studies 
demonstrated the resistance reversal effect of a calcium channel blocker verapamil 
(Bray et al., 1994 and Martin et al., 1987). It was commonly accepted that an increase 
in the pH of the food vacuole might account for the decreased accumulation of CQ 
inside the food vacuole thus leading to resistance. However studies by Ursos and co-
workers (2000) contradicted this hypothesis and showed a decrease in the pH of the 
food vacuole. Further studies showed that the pH of the food vacuole influences the 
ratio of soluble/insoluble heme (Dzekunov et al., 2000). The lower pH promotes the 
formation of insoluble heme thus reduces the amount of soluble heme available for 
CQ binding. The exact mechanism of resistance is still debated and it is possible that 



















1.9.2 Artemisia annua 
 
1.9.2.1 History of Artemisia annua 
 
Artemisia annua is indigenous to China and references in ancient Chinese documents 
date back as far as 168 BC (Hien et al., 1993). The ancient Chinese referred to this 
plant as ‘Qing Hao’ which means ‘green herb’. The Chinese have used A. annua for at 
least 2000 years to treat fevers and malaria (Meshnick et al., 2002). This plant was 
traditionally administered as a tea. Antimalarial activity was observed with other 
Artemisia sp. other than A. annua (Valencha et al., 1994). These other species of 
Artemisia most likely contain novel antimalarial compounds. Clinical efficacy of A. 
annua has not been well studied. Several clinical studies sho ed that herbal 
preparations of A. annua are effective against malaria (Hirt et al., 2000 and Mueller et 
al., 2000). The use of herbal preparations of this plant could be an alternative 
treatment for the large number of patients who do not access treatment due to a lack 
of antimalarials. Small-scale cultivation and local utilisation of the herbal preparation 
of A. annua is encouraged by non-governmental organisations (Anamed, 2008). 
However aqueous preparations of A. annua contain significantly lower artemisinin 
(ART) concentrations than the WHO recommendations (Räth et al., 2004). These low 
concentrations in herbal remedies can lead to the development of resistance. 
 
1.9.2.2 Artemisinin-based antimalarials 
 
ART was first isolated in China in 1971 from A. annua (Hien et al., 1993). The leaves 
and flowers of the plant contain ART. Tan et al. (1998) showed that only two other 
Artemisia spp. namely A. apiacea and A. lancea contain ART. The semisynthetic 
derivatives artesunate, artemether and arteether have been developed from ART 
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Figure 4 Chemical structures of artemisinin and its derivatives 
 
ART and its derivatives are the most powerful antimalarial drugs in history and act as 
prodrugs that have the same active metabolite, dihydroartemisinin (White et al., 
1994). There are no reports on the toxic effects of A. annua or ART, although at high 
doses ART can be neurotoxic but this has not been observed in clinical studies. The 
administration of ART is limited to oral and rectal routes due to the poor solubility of 
ART in oil and water (Ashton et al., 1998). Synthetic analogues artesunate and 
artemether of ART are more soluble and can be administered intravenously and 
intramuscularly (Van Agtmael et al 1999). Artesunate has the most rapid therapeutic 
response (White et al., 1994). ART is a sesquiterpene lactone containing an 
endoperoxide group which bridges an oxygen-containing ring. The structure of ART 
has challenged the minds of many medicinal chemists but no cost-effective synthesis 
has been developed. The aerial parts of A. annua are still the major source of ART. 
Biotechnology has enabled the commercial cultivation of A. annua to maximise the 

















ART is one of twenty nine sesquiterpenes in A. annua and many of these compounds 
are in greater quantities than ART in wild strains of the plant (Liu et al., 1992). ART 
is a lipophilic compound but the traditional preparation of A. annua is as an aqueous 
decoction. Congener constituents of the plant can aid in solubility and enhance the 
activity of ART as demonstrated in vitro with flavonoids. Further studies reported that 
flavones have no effect on heme but catalyse the reaction of ART with heme (Bilia et 
al., 2002). Flavones can also help with the solubility of ART in the herbal preparation. 
Several studies concluded that the antimalarial properties of A. annua are not only due 
to ART but a combination of compounds. Different compounds in the herbal 
preparation might inhibit metabolising enzymes. The pharmacokinetics of ART from 
the herbal preparation has not been fully studied. Recent studies by Räth et al. (2004) 
showed that the bioavailability of ART from an infusion of A. annua is considerably 
less than pure ART.  Treatment with ART results in a decrease of ART concentration 
in plasma and an increased concentration of the metabolite dehydroartemisinin (Van 
Agtmael et al., 1999). Contrary to modern belief combination therapy has been used 
in traditional medicine for hundreds of years.  
 
ART unlike quinine-based and antifolate antimalarials is gametocytocidal thus 
reducing the potential transmission of malaria (Price et al., 1996). The commonly 
quoted affordable limit of $1 for a course of antimalarial treatment was already too 
high for developing countries (Wilcox et al., 2001 and Wilcox et al., 2004a). The 
WHO recommends that these drugs be used in combination with other antimalarial 
drugs. The cost of ART-based combination therapy is effective yet unaffordable to the 
communities which need it the most. This sensitive situation has led to exploitation as 
fake artesunate is being sold in Southeast Asia (Newton et al., 2002).  
 
1.9.2.3 Mechanism of action and resistance 
 
The structure of ART is very different from quinine-derived antimalarials. Quinine 
alkaloids are basic and ART is neutral and non-polar. Given the structural difference 
between these two classes of drugs the mechanism of action against the malaria 
parasite is also different. The mechanism of action of ART involves its interaction 














parasite molecules thus disrupting the normal metabolic pathways of the parasite. The 
mechanism of action of ART still remains a controversial subject. Several hypotheses 
exists which include its reaction with heme and the reduction of the peroxide by 
ferroprotophyrin IX resulting in active intermediates which can react with heme and 
essential parasite proteins. Ponwee and co-workers (2007) showed that ART interacts 
with heme and heme-containing proteins which results in reduced ART effectiveness. 
The exact method by which ART-reactive products interfere with metabolic pathways 
and kill the parasite is still not clear (Orjih et al., 1996). The activity of ART is 
specific as it reacts only with free heme and not with haemoglobin of uninfected red 
blood cells (Hong et al., 1994). The effect of ART is antagonised by iron chelators 
and also by CQ which binds to heme (Meshnick et al., 1993). The mechanism of 
action of ART is also associated with the alkylation of heme and the parasite 
mitochondria and membrane (Maeno et al., 1993 and Meshnick et al., 1994). ART 
and its derivatives without combination therapy can result in recrudescence after two 
weeks of treatment which might be due to insufficient availability of heme as the 
parasites might not be in the growth phase during exposure to the drug. Furthermore 
the WHO has banned the use of oral ART monotherapies in an effort to prevent the 
development of drug-resistance (WHO, 2007).  
 
An artemether-quinine meta-analysis of clinical trials showed that artemether is at 
least as effective as quinine and resulted in fewer serious adverse effects. Chinese 
Plasmodium strains are less sensitive to ART than African strains (Wongsrichanalai et 
al., 1997). This might be due to the centuries of exposure to A. annua in China. 
Resistance is more likely to develop against a single compound than a combination of 
compounds as found in herbal preparations. ART-resistant parasites have been 
cultivated in vitro with α-thalassemic erythrocytes (Ponmee et al., 2007). The shorter 
half-life of ART can be advantageous against resistance development because the 
parasite is exposed to shorter periods of sub-therapeutic levels. ART may stimulate 


















1.9.3 Antifolate antimalarial drugs 
 
Antifolates are the oldest antimetabolite class of anticancer drugs. CQ-resistance led 
to antifolate treatment of malaria mainly using combinations of pyrimethamine (PYR) 
and sulfadoxine (SFD). Antifolate chemotherapy is widely used for malaria however 






































Figure 5 Chemical structures of the antifolate drugs 
 
The molecular targets of these drugs are folate-dependaent enzymes defined as 
dihydrofolate reductase (dhfr) for PYR and dihydropteroate synthetase (dhps) for SFD 






















1.9.4 Promising antimalarial medicinal plants and plant-based 
compounds 
 
The antimalarial activity of approximately 600 plants representing 129 families was 
published by Spencer et al. (1947).  Several plants were identified as promising leads 
including the Asian medicinal plant Brucea javanica. Antiplasmodial quassinoids 
were later isolated from the fruits of B. javanica (O’Neill et al., 1987). In vivo studies 
on the crude extract showed high activity but also high toxicity. The observed toxicity 
lends some support in the aqueous preparation used traditionally. Allen and co-
workers (1994) showed that the aqueous extract of B. javanica antagonised the effect 
of CQ in vitro against CQR strains of P. falciparum. These studies suggested that co-
administration of this TM with CQ might lead to treatment failure which can 
subsequently result in the development of resistance.  
 
Berberine occurs in several plant families including Annonaceae and Menispermaceae 
which is widely used in the treatment of malaria, amoebiasis and leishmaniasis 
(Phillipson et al., 1993 and Vennerstrom et al., 1988). This alkaloid has shown to be 
active in vitro against P. falciparum but no in vivo activity was observed. Cryptolepis 
sanguinolenta is traditionally used in Ghana to treat malaria and was reported to be 
clinically effective (Kirby et al., 1995b and Paulo et al., 2000). An antiplasmodial 
indoloquinoline, cryptolepine, was isolated from this plant. Cryptolepine, like 
berberine, was active in vitro against P. falciparum but did not show in vivo activity. 
Studies suggested that cryptolepine intercalate with DNA which could account for its 
potent in vitro activity.  
 
Changshan is an ancient Chinese febrifuge mixture of plants with the key ingredient 
being Dichroa febrifuga (Miyasita et al., 1979). The active constituents of D. 
febrifuga namely β-dichroine (febrifugine) and α-dichroine (isofebrifugine) were 
isolated early in the twentieth century (Jang et al., 1948 and Koepfli et al., 1950). The 
antiplasmodial activity of D. febrifuga was observed against in vivo avian malaria 
(Spencer et al., 1947). Febrifugine was 100 fold more active than quinine in an avian 
malaria model (Koepfli et al., 1947). Ultimately the emetic effect of D. febrifuga and 














Phaeanthine is a bisbenzylisoquinoline alkaloid isolated from Triclisia patens was 
shown to be more active in vitro against the CQR K1 strain than the CQS T9-96 strain 
of P. falciparum (Ekong et al., 1991). Combination experiments with phaeanthine and 
CQ showed antagonism against the CQS strain and an additive effect against the CQR 
strain. 
 
The 1,2,4-trioxane group of the ART molecule produces radicals which cause parasite 
death (Robert et al., 2002). Chimeric compounds named trioxaquines contain the 
trioxane entity responsible for ART activity and an aminoquinoline entity responsible 
for antiplasmodial potency of CQ (Basco et al., 2001). Trioxaquines have shown 
promising in vitro and in vivo activity against CQR strains (Dechy-Cabaret et al., 
2004 and Benoit-Vical et al., 2007). This class of compounds is active against both 
sexual and asexual stages of the parasite life-cycle and also showed low cytotoxicity.  








































1.10 Scope of the study 
 
The purpose of this study was to use an ethnopharmacological approach to isolate 
novel antiplasmodial compounds from Siphonochilus aethiopicus and Aloe ferox. 
 
The first objective was to isolate and characterise novel antiplasmodial compounds 
and evaluate schizontocidal activity using a malaria-mouse model.   
 
The processes followed were: 
- In vitro and in vivo bioactivity testing as well as in vitro cytotoxicity testing 
- Isolation and structural elucidation of antiplasmodial compounds 
 
Secondly, the objective was to investigate the bioavailability and metabolism of the 
most promising compound in an in vivo system.  
 
The processes followed were: 
- Bioavailability study of the most active compound 


























































2 Literature review of plants  
 
Aloe ferox and Siphonochilus aethiopicus are commonly used as traditional medicines. 
These two medicinal plants were selected for this study based on traditional knowledge 
and previous antiplasmodial activity. 
 




Aloe ferox photographed by C.Lategan (Kirstenbosch Botanical Gardens, Cape Town) 
 
Aloe ferox Mill. Asphodelaceae (formerly classified as Liliaceae) is a single stemmed 
Aloe which produces red or orange flowers from May to August (van Wyk et al., 1996 
and Hutchings et al., 1996). Ferox means ferocious which refers to the prickly leaves. 
There are approximately 330 Aloe species (Trease and Evans et al., 1978). The history of 
aloes dates back to the fourth century B.C. and was well known by the Greeks. The aloe 
plant is believed to be the main reason for Alexander the Great to conquer the island of 























Dried leaf exudates of A. ferox (Cape Aloe) and products of Cape aloe. Photographs 














Aloes are used all over the world by various populations and the species used depends 
mainly on availability in local regions (Loots et al., 2007). A. ferox is indigenous to 
South Africa and is widely distributed from Swellendam to the Western Cape, Eastern 
Cape and southern Kwazulu-Natal provinces, some parts of south-western Lesotho 
and south-eastern Free State regions (van Wyk et al., 1996). A. ferox is commonly 
known as bitteraalwyn (Afrikaans), bitter aloe (English) or umhlaba (Xhosa, Zulu or 
Sotho) (van Wyk et al., 1997). A. ferox has extensive medicinal usage ranging from an 
insect repellent, the healing of sores, blisters, cuts; treating acne, burns, sinusitis, 
syphilis, stomach complaints and various other ailments (TRAMED III, 2001). The 
leaves or roots are boiled in water to treat arthritis, eczema, conjunctivitis, 
hypertension, stress and are also used as a laxative. Fresh leaf juice is used to treat 
ophthalmia and ground leaves are used as snuff (Hutchings et al., 1996). Venereal 
sores are treated with leaf decoctions and powder of charred ground leaves. The 
nectar might have a narcotic effect (Watt and Breyer-Brandwijk et al., 1962). A 
medicinal product derived from A. ferox called Cape Aloe is used for stomach 
complaints and as a laxative. This product was first exported in 1780 and is now 
mainly exported to Europe but also marketed and used locally (Trease and Evans et 
al., 1978; van Wyk et al., 1996). Cape Aloe is still prepared by an age old method 
with little modification. Aloin is known as the active compound responsible for the 
purgative characteristic of A. ferox. It was found that aloin acts as a prodrug for aloe-
emodin which is formed in the colon. A guideline for export quality Cape Aloe 
product is that it should contain at least 18% aloin. Seasonal variation of aloin in leaf 
juice has been observed (Trease and Evans et al., 1996). Aloe gel mainly from A. vera 
is widely used in the food and cosmetic industry (van Wyk et al., 1996). Aloe plants 
are cultivated for commercial purposes in the West Indies, East Africa, north-west 
India and southern China. A. ferox leaf gel is now also being produced for these 
lucrative industries. The gel which is rich in polysaccharides, polyphenols, 
phytosterols and indoles may be of therapeutic benefit (Loots et al., 2007).  
 
A. ferox is used to treat sexually transmitted infections in the Eastern Cape region of 
South Africa and in the treatment of syphilis in West Africa (Kambizi et al., 2004, 
Watt and Breyer-Brandwijk et al., 1962 and Hutchings et al., 1996). The investigation 














compounds namely aloe-emodin, chrysophanol and aloin A.  Aloe-emodin has been 
reported to have anti-tumor activity (Trease and Evans et al., 1978). Metabolism 
studies revealed that chrysophanol undergoes biotransformation by CYP enzymes to 
produce aloe-emodin (Mueller et al., 1998). Genotoxicity testing showed that the 
aloe-emodin metabolite is a more potent inducer of micronuclei than chrysophanol. 
Further studies showed that aloe-emodin has anticancer activity with selectivity 
against neuroectodermal tumors (Pecere et al., 2000). Aloe-emodin was identified as a 
potential anti-tumor agent and led to pharmacokinetic studies which can be used for 
pre-clinical investigations (Zaffaroni et al., 2003). Aloe species have been investigated 
for their anti-inflammatory and wound healing properties (Heggers et al., 1979, 
Cappaso et al., 1983, Klein et al., 1988, Lindsey et al., 2002). The complexity of the 
inflammatory process and wound healing may be addressed by different gel 
components (Lindsey et al., 2002). A. ferox showed an 80% cylooxygenase inhibition 
but the group of compounds responsible for the observed anti-inflammatory activity 
was not identified. Earlier studies showed that emodin, aloe-emodin and aloin can be 
metabolised by the Koble reaction to produce salicylates (Klein and Penneys et al., 
1988). Salicylic acid is known for its analgesic and anti-inflammatory properties as 
has been demonstrated in A. vera (Robson et al., 1982). However recent studies on 
Cape aloe showed that aloeresin I has good anti-inflammatory activity (Speranza et 
al., 2005). The antimalarial drug chloroquine has also been shown to be effective as 
an anti-inflammatory drug (Mackenzie et al., 1983). Medicinal plants used to treat 
inflammation can potentially be useful against malaria. Aloe species have previously 
been investigated for in vitro antiplasmodial activity against P. falciparum but no 
significant activity was observed (van Zyl et al., 2002).  Aloin was not active against 
the malaria parasite. Recently, A. ferox was tested for in vitro antiplasmodial activity 
and revealed several promising results (Clarkson et al., 2004).  
 
The phytochemistry of aloes has been studied since 1851 with the first preparation of 
the major compound aloin from Barbados aloes (Trease and Evans et al., 1978). 
Extensive phytochemical investigations of Aloe species have led to the isolation of 
known as well as novel compounds. Aloes are known to contain anthraquinones, 
chromones aloeresins and aloesin as well as glycosides such as aloin and barbaloin 














2005, Speranza et al., 1997, Bisrat et al., 2000, Dagne et al., 1997, Trease and Evans 
et al., 1978). Chromones and anthrones are the main secondary metabolites in Aloe 
species (Esteban-Carrasco et al., 2001). Derivatives of these compounds occur 




















An investigation of the essential oil of the A. ferox leaves identified 21 compounds 
(Magwa et al., 2006). Leaf exudates revealed the presence of aloesin, aloeresin A, 
aloin A and B, aloinoside A and B, and a novel 1-methyl tetralin derivative namely 
feroxidin (Viljoen et al., 2001 and Speranza et al., 1990).  Fresh leaf juice undergoes 
thermal treatment to produce the commercial bittering product, Cape Aloe. Process 
products play an important role in the safety, nutrition and flavour of foods. A study 
investigating the process products of prolonged heating resulted in the isolation of a 
novel benzochromanone derivative (Speranza et al., 1996). The roots of 172 Aloe 
species were investigated in a chemotaxonomic survey using chemical markers such 
as anthraquinones and pre-anthraquinones at an infrageneric level (van Wyk et al., 
1995). The study identified the major components in A. ferox roots to be 
chrysophanol, asphodeline, aloesaponarin I and II, as well as aloesaponol I and II. 
Broad chemotaxonomic screens of a variety of Aloe species have contributed to 
understanding natural relationships (Viljoen et al., 2002a). Several aloes have shown 
chemical similarities between morphologically and geographically diverse species 























Leaves, flowers and rhizomes of S. aethiopicus. Photographs obtained from Medicinal 
Plants of South Africa (van Wyk et al., 1997) 
 
Siphonochilus aethiopicus (Schweinf) B.L Burtt belongs to the Zingiberaceae family 
(van Wyk, et al., 1997). The Zingiberaceae family has 49 genera and 1 300 species 
consisting of perennial aromatic herbs with fleshy rhizomes and tuberous roots 
(Trease and Evans et al., 1978). The family is known for its volatile oils and pungent 
characteristics. S. aethiopicus was previously described as a Kaempferia sp. known as 
K. aethiopica or K. ethelae (Hutchings et al., 1996). Plants which are known for their 
culinary purposes like ginger (Zingiber officinale) and turmeric (Curcuma longa) 
belong to the Zingiberaceae family (Watt and Breyer-Brandwijk et al., 1962). 
Turmeric is used as traditional medicine to treat several ailments such as headache 
jaundice, skin disease and hepatitis throughout Africa, India and Mauritius, and is also 
cultivated in India, West Pakistan, China and Malaysia (Trease and Evans et al., 1996; 
Watt and Breyer-Brandwijk et al., 1962). Ginger is traditionally used to treat 
headache, rheumatism, and cough. It is also used as a mosquito repellent and wound 
dressing. Varieties of the ginger grow in Africa, Jamaica, China and India. The 
rhizomes and leaves of S. aethiopicus have a similar smell to that of ginger but no 














roots are chewed as traditional medicine. During the growing season rhizomes and 
roots are used while in winter the rhizomes are used without roots or leaves. The 
rhizomes are traditionally used to treat colds, coughs, influenza, hysteria, pain, asthma 
and dysmenorrhoea. S. aethiopicus is used by the Swazi to treat malaria and chewed 
by women to relieve pain during menstruation (Hutchings et al., 1996; Watt and 
Breyer-Brandwijk et al., 1962). Cold rhizome infusions are administered to horses 
against horse sickness. An overdose can stupefy horses. Wild ginger was identified as 
one of the most frequently used medicinal plants in South Africa (Stafford et al., 
2005). The harvesting of rhizomes for traditional medicine has resulted in it almost 
being extinct in the wild (Zschocke et al., 2000). There is growing scientific support 
to conserve endangered medicinal plants using plant part substitution and to 
investigate genetic diversity for cultivation purposes (Zschocke et al., 2000, Viljoen et 
al., 2002b, Makhuvha et al., 1997). Wild ginger is easily cultivated in warm parts of 
South Africa and attempts at large-scale production of rhizomes using tissue culture is 
being researched (van Wyk, et al., 1997). The chemical profile and essential oil 
composition of rhizomes and roots are almost identical (Zschocke et al., 2000 and 
Viljoen et al., 2002b). These studies encourage the use of roots and the replanting of 
rhizomes to conserve this important medicinal plant. Scientific research has played a 
major role in conservation and cultivation. Cultivated plants have decreased the 
pressure imposed on wild populations. 
 
S. aethiopicus was previously scientifically investigated for some of its traditional 
uses. The ethanol extract of the rhizomes has shown activity against Bacillus subtilis, 
Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae (Stafford et al., 
2005). The ethanol extract of the leaves and tubers or stems showed better anti-
inflammatory activity than the roots and rhizomes (Lindsey et al., 1999 and Zschocke 
et al., 2000). However the underground parts of the plant are mostly used for 
traditional medicine. Interestingly the ethanol extract of the rhizomes showed an 
increase in anti-inflammatory and antibacterial activity after 90 days of storage 
(Stafford et al., 2005). The water extracts were less active after storage which might 
explain why traditional healers prepare fresh stocks. Anti-inflammatory studies 
revealed that S. aethiopicus inhibits the prostaglandin biosynthesis pathway but has no 














potentially useful to treat dysmenorrhoea. The rhizomes of mature plants showed 
significantly higher anti-inflammatory activity than younger smaller plants (Zschocke 
et al., 2000). Thus plants may have to be a certain age or size for harvesting.  
 
Although wild ginger is widely used limited information is available about its 
phytochemistry. Attempts at isolating anti-inflammatory compounds revealed that the 
activity of the crude extract might be due to synergism (Jäger et al., 2005). Galenic 
preparations may not always have the same clinical response as isolated drugs (Trease 
and Evans et al., 1978). Synergism may be due to the complex nature of plant 
extracts. A chemotaxonomic survey led to the isolation of two novel furanoterpenoids 
from S. aethiopicus (Holzapfel et al., 2002). The major compound 4aαH-3,5α,8aβ-
trimethyl-4,4a,9-tetrahydro-naphtho[2,3-b]-furan-8-one was named siphonochilone 
and represents 20 – 30% of the essential oil composition of rhizomes and roots 
(Viljoen et al., 2002b). Wild ginger has been scientifically investigated for its use as 
an anti-septic, pain-reliever and use during menstruation. However, to our knowledge, 











                                                                                                                                                                             
Chemical structures of compounds isolated or derived from S. aethiopicus (Holzapfel 
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Isolation and characterization of 


















S. aethiopicus was investigated for the presence of novel antiplasmodial compounds 
using chromatographic techniques such as solid phase extraction (SPE), liquid-liquid 
extraction and high performance liquid chromatography (HPLC). The extracts and 
compounds were screened for in vitro antiplasmodial activity and cytotoxicity 
(Chapter 7). Compounds were also tested for antimycobacterial, antibacterial and 
antifungal activity. Structure elucidation was determined using spectral data such as 
1H, 13C, HSQC, HMQC, COSY and NOESY NMR spectra as well as HR-EI-MS 
spectra.  
 
3.2 Bioassay-guided fractionation 
 
The rhizomes of S. aethiopicus were extracted with ethyl acetate (EA) and the yields 
determined (3.5%). S. aethiopicus was fractionated using a combination of 




Scheme 2 Fractionation procedure of S. aethiopicus extract 
 
The EA extract was fractionated using SPE methods (7.3.1). Enhancement in activity 
was observed with the 50% to 80% acetonitrile (ACN) SPE fractions compared to the 
S. aethiopicus (EA) extract 
HPLC (analytical and semi-preparative) 














crude extract (Fig 6). The concentration inhibiting 50% of growth (IC50) is given as a 
mean value of 4 independent experiments. 
SPE fractions against P.falciparum D10 strain




























Figure 7 HPLC profiles of SPE fractions on a C18 RP column (λ = 254 nm)  
HPLC conditions: Mobile phase ACN:H2O using a gradient of 10 – 100% ACN (20 
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Figure 8 Continued HPLC profiles of SPE fractions  
 
Two major peaks were present in the HPLC profiles of the SPE fractions (Fig 7 and 
8). Fractionation of the crude extract was optimised via liquid-liquid extraction by 
using EA and a range of pH buffers described in Chapter 7 (7.3.2). This fractionation 
process was not as time consuming as SPE. 
 
pH extraction of compound 3
















Figure 9 HPLC analyses of pH extractions of compound 3  
 
pH 3 and 11 showed good enhancement in extraction of the active peak (Fig 9). The 
acidic nature of pH 3 was undesirable for large scale extraction as compounds might 
be unstable at this pH. pH 11 was selected for large scale extraction. Further 
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Figure 10 HPLC profile of liquid-liquid fraction on a C18 RP column (λ = 254 nm)  
HPLC conditions: Mobile phase H2O:ACN using a gradient of 10 – 100% ACN (20 





Figure 11 HPLC profiles and UV absorption spectra of compounds 1 – 3  
 
The SPE fractions were purified via semi-preparative HPLC and resulted in the 
isolation of three peaks (Fig 11). The structure elucidation of isolated compounds (1 – 
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Figure 13 Chemical structures of compounds previously isolated and derived from S. 
aethiopicus  
 
Previous studies have led to the isolation of two furanoterpenoid derivatives namely,  
4aαH-3,5α,8aβ-trimethyl-4,4a,9-tetrahydro-naphtho[2,3-b]-furan-8-one and 2-
hydroxy-4aαH-3,5α,8aβ-trimethyl-4,4a,9-tetrahydronaphtho[2,3-b]-furan-8-one, from 
S. aethiopicus (Holzapfel et al., 2002). In this study a further three novel compounds 
were isolated from this plant. To our knowledge this is the first time that these 
compounds have been isolated. The compounds were characterised by 1H, 13C, 
HSQC, HMQC, NOESY, COSY and HR-APCI-MS data. The spectral data for rings 
A and B compared well with previously published data but significant differences 
were observed for ring C (Fig 12 and Fig 13). 
Compound 1: R = OH-group 
Compound 2: R = H-group 
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Table 11H, 13C, HSQC, HMQC, NOESY and COSY spectral data of compound1 
Position   δH (ppm) δC (ppm) HMQC NOESY COSY 
              
2    171.6 s       
3     122.4 s       
3a     160.1 s       
4 α 2.90 dd (13.3; 3.6 Hz) 25.3 t C-3; C-3a; C-4a; C-9a CH3-3; CH3-5 H-4a; H-4β 
  β 2.36 dd (13.5; 13.3 Hz)   C-3; C-3a; C-4a H-5β; CH3-8a H-4a; H-4α 
4a   1.62 ddd (9.0; 9.0; 3.6 Hz) 51.1 d C-8; C-8a; CH3-8a   H-4α; H-4β; H-5β 
5 β 2.53 tq (7.2; 2.4 Hz) 35.3 d C-4a; C-8a CH3-8a H-4a; CH3-5 
6   6.74 dd (10.2; 1.8 Hz) 156.0 d C4a; CH3-5   H-7 
7   5.81 dd (10.2; 3.0 Hz) 126.8 d     H-6 
8    204.3 s       
8a     46.4 s       
9 α 2.49 d (14.1 Hz) 44.8 t C-3a; C-4a; C-8a; C-9a; CH3-8a   H-9β 
  β 1.60 d (14.1 Hz)   C-8; C-8a; C-9a; CH3-8a   H-9α 
9a     104.5 s       
3-Me   1.78 d (1.2 Hz) 8.9 q C-2; C-3; C-3a H-4α   
5-Me   1.22 d (7.2 Hz) 18.9 q C-4a; C-5; C-6 H-4α H-5β 
8a-Me   1.30 s 17.8 q C-4a; C-8; C-8a; C-9 H-4β; H-5β ; 9a-OH   
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3.3.1 Compound 1 
 
Compound 1 named 9aβ-Hydroxy 4aαH-3,5α,8aβ-trimethyl-4,4a,8a,9-
tetrahydronaphtho-([2,3b]-dihydrofuran-2-one)-8-one was obtained as a pale yellow 




°−=α , melting point 179.1°C (yield from EA extract = 
4.39%). The molecular formula was established as C15H18O4 from the [M+1]
+ ion at 
263.1278 in the HR-APCI-MS data (calculated mass m/z 263.1283). Investigation of 
the MS data revealed the most abundant fragment at a mass of m/z 245.1200, which 
indicated a loss of an H2O-group. The NMR results for compound 1 are summarised 
in Table 1. 
 
Ring A: The HMQC spectrum identified quaternary carbons C-2 (δ 171.6), C-3 (δ 
122.4), C-3a (δ 160.1), C-8 (δ 204.3) and C-8a (δ 46.3). The structure determination 
was initiated at the most deshielded proton H-6, resonating at δ 6.74 as a double-
doublet (J=10.2Hz; 1.8Hz). This chemical shift is indicative of an aromatic proton or 
conjugated double bond system. Coupling constants of 10.2Hz are typical of vicinal-
coupling across a double bond or ortho-coupling in an aromatic system. The coupling 
constant at H-6 of 1.8Hz can be attributed to long range coupling. A second proton 
with a coupling constant of 10.2Hz was identified as H-7 (δ 5.81). The COSY 
spectrum confirmed that the protons at δ 6.74 and δ 5.81 are coupled. The chemical 
shift at δ 5.81 is too shielded for an aromatic proton thus suggesting a carbon-carbon 
double bond in a non-aromatic system. An aromatic system was thus eliminated as a 
possibility. The large coupling constant of 10.2Hz can be accounted for by vicinal-
coupling.  
 
Although COSY correlations suggest a d splitting pattern at H-7 the multiplicity 
appears as a dd due to long range allylic coupling with H-5 (J=3Hz) (Lambert et al., 
1998). The HSQC spectrum identified the carbon resonating at δ 126.8 as C-7, and the 
carbon at δ 156.0 as C-6.  The chemical shifts of the carbons C-6 and C-7 are typical 
of a α,β-unsaturated carbonyl system (Breitmaier et al., 1987). In the α,β-unsaturated 
carbonyl system C-6 is the deshielded β-carbon and C-7 is the α-carbon (Lambert, 
1998). H-6 is coupled to C-4a (δ 51.1) and C-5Me (δ 18.9) in the HMQC spectrum. 
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identified a triple quartet resonating at δ 2.53 (J=7.2Hz; 2.4Hz) as H-5. 
Complementary evidence from the HSQC and COSY spectra confirmed that the 
carbon at δ 35.5 is C-5. The NOESY spectrum coupled H-5 to methyl protons 
resonating as a singlet at δ 1.30 (8aMe) indicating that the protons have the same 
spacial orientation. The d resonating at δ 1.22 (J=7.2Hz) was assigned to 5Me in the 
HSQC spectrum. The HMQC data linked 5-Me to C-4a (δ 51.1) and C-5. Evidence 
from the NOESY spectrum revealed coupling between 5-Me and H-4α. This indicates 
that 5-Me has the same spacial orientation as H-4α. The COSY spectrum also coupled 
H-5 to 5-Me and H-4a resonating at δ 1.62 (J=9.0Hz; 9.0Hz; 3.6Hz). The multiplicity 
at H-4a appears as a ddd due to splitting by H-5, H-4α and H-4β as revealed by 
coupling shown in the COSY spectrum. The HSQC spectrum identified the carbon at 
δ 51.1 as C-4a. The NOESY spectrum coupled H-4a to 5Me. The orientation of these 
protons is α. The HMQC spectrum coupled C-4a to a carbonyl carbon resonating at δ 
204.3 assigned as C-8. 
 
Ring B: The COSY spectrum coupled H-4a to H-4α at δ 2.90 (J=13.2Hz; 3.6Hz) and 
H-4β at δ 2.35 (J=13.2Hz; 3.6Hz). Supporting evidence from the HSQC spectrum 
coupled these protons to the same carbon at δ 25.3 identified as C-4. Geminal 
(J=13.2Hz) and vicinal (J=3.6Hz) coupling suggests dd multiplicities for both H-4α 
and H-4β. However the multiplicity at H-4β appeared as overlapping dd's not clearly 
defined. The COSY spectrum coupled H-4α to H-4β and both to H-4a. The 
assignment of H-4α was further supported by the NOESY correlations to 3Me and 
5Me. The HMQC spectrum showed correlations between H-4α and H-4β to C-3, C-
3a, and C-4a and i  addition H-4α also coupled to C-9a. The methyl group resonating 
as a singlet at δ 1.30 was assigned as 8a-Me. Orientation of 8aMe in the β-position 
was supported by coupling to H-4β and H-5 in the NOESY spectrum. Complimentary 
evidence from the HMQC spectrum linked 8a-Me to C-4a, C-8, C-8a and C-9. This 
further supported the assignment of 8a-Me in the molecule.  
 
The HSQC spectrum linked H-9α and H-9β to the same carbon at δ 44.8 (C-9). H-9α 
was assigned to the d resonating at δ 2.49 with a geminal coupling constant of 
J=14.1Hz. Complementary evidence was obtained from the HMQC spectrum which 
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9α to a d resonating at δ 1.6 (J=14.1Hz) identified as H-9β. Further evidence from the 
HMQC spectrum correlated H-9β to C-8, C-8a, 8a-Me and C-9a. 
 
Ring C: A second α, β-unsaturated carbonyl system was identified at C-3a (δ 160.1) 
and C-3 (δ 122.4). C-3a is the deshielded α-carbon and C-3 the β-carbon. 3Me (δ 8.9) 
coupled to C-3, C-3a and C-2 in the HMQC spectrum. The attachment of 3-Me to C-3 
confirms that C-3 is a methyl constituent at the β-carbon in the α, β-unsaturated 
carbonyl system (Lambert, 1998). 3-Me resonated as a d at δ 1.78 (J=1.2Hz) and this 
multiplicity can be accounted for by long range allylic coupling with H-4α as revealed 
in the COSY spectrum. The location of the OH-group was convincingly established at 
C-9a based on a molecular model as well as the conversions of compounds 1 to 2 and 
2 to 3. 
 
3.3.2 Compound 2 
 
Compound 2 named 4aαH-3,5α,8aβ-Trimethyl-4,4a,8a,9-tetrahydronaphtho-([2,3b]-
dihydrofuran-2-one)-8-one was obtained as a yellow oily 




°+=α , melting point 60°C (yield from EA extract = 
2.62%). Compound 2 gave a [M+H]+ ion in the HR-APCI-MS data at 247.1340, 
which corresponded to the molecular formula of C15H18O3 (calculated mass m/z 
247.1334). The NMR data of compound 2 was comparable to compound 1 for ring A 
and B but differences were observed in ring C (Fig 12 and Table 2). 
 
Ring C: A difference of 16D between M1
+ and M2
+, indicated the replacement of the 
OH group at C-9a by an H atom. This was confirmed by the appearance of a dd at δ  
4.9 coupled in the COSY spectrum to the H-9α and H-9β dd’s at δ  2.66 and δ  1.62, 
respectively (Table 2). Further confirmation came from the correlation between H-9a 
and C-3a in the HMQC spectrum. Finally a NOESY correlation between H-9a and 
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Table 2 1H, 13C, HSQC, HMQC, NOESY and COSY spectral data of compound2 
 
Position   δH (ppm) δC (ppm) HMQC NOESY COSY 
              
2     174.2 s       
3     119.7 s       
3a     161.0 s       
4 α 3.03 dd (14.3; 4.8 Hz) 25.2 t C-3; C-3a; C-4a; C-5; C-8a; C-9 CH3-3; CH3-5 H-4β; H-4a 
  β 2.31 dd (14.3; 12.0 Hz)   C-3; C-3a; C-4a; C-5 H-5β; CH3-8a H-4α; H-4a 
4a   1.64 dd (13.8; 4.2 Hz) 48.1 d C-4; C-5; CH3-5; C-8; C-8a; CH3-8a   H-4a; H-4β; H-5β 
5 β 2.50 tq (7.2; 2.4 Hz) 36.4 d   H-4β; CH3-8a H-4a; CH3-5 
6   6.76 dd (10.2; 1.8 Hz) 154.5 d C-4a; C-5; CH3-5; C-8   H-7 
7   5.84 dd (10.2; 2.4 Hz) 125.3 d C-5; C-8a   H-6 
8     202.2 s       
8a     44.9 s       
9 α 2.66 dd (12.9; 6.0 Hz) 39.6 t C-3a; C-4a; C-8a;  CH3-8a; C-9a   H-9β 
  β 1.63 dd (12.9; 4.2 Hz)   C-3a; C-4a; C-8; C-8a; CH3-8a   H-9α 
9a   4.90 dd (16.0; 6.6 Hz) 77.8 d C-3a  CH3-8a H-9α; H-9β 
3-Me   1.78 d (1.2 Hz) 7.4 q C-2; C-3; C-3a H-4α   
5-Me   1.21 d (7.2 Hz) 17.3 q C-4a; C-5; C-6 H-4α H-5β 
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Figure 14 Chemical structure of compound 3  
 
Compound 3 named 4aαH-3,5α,8aβ-Trimethyl-4,4a,8a-trihydronaphtho-([2,3b]-
dihydrofuran-2-one)-8-one was obtained as a yellow 




°+=α , melting point 77°C (yield from EA extract = 
1.89%). The molecular formula, C15H16O3, was deduced from the [M+H]
+ ion at 
245.1161 in the HR-APCI-MS data (calculated 245.1178). The NMR data of 
compound 3 was comparable to compounds 1 and 2 except for differences observed 
with ring C (Fig 14 and Table 3). 
 
Ring C: A difference of 2D between compound 2 and 3 could be attributed to the 
formation of an olefinic double bond between C-9 and C-9a. Confirmation came from 
the appearance of a proton singlet at  δ 6.29 and 2JCH and 3JCH correlations from H-9 
to C-9a, C-3a, C-4a and C-8 (Table 3). The additional α,β,γ-conjugation resulted in a 
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Table 3 1H, 13C, HSQC, HMQC, NOESY and COSY spectral data of compound3 
 
Position   δH (ppm) δC (ppm) HMQC NOESY COSY 
              
2     170.9 s       
3     117.3 s       
3a     146.8 s       
4 α 3.06 dd (17.4; 4.8 Hz) 22.4 t C-3; C-3a; C-4a; C-9a CH3-5 H-4β; H-4a 
  β 2.52 dd (17.4; 1.8 Hz)     CH3-8a H-4α; H-4a 
4a   2.02 ddd (13.2; 11.8; 4.2 Hz) 46.5 s C-3a   H-4α; H-4β 
5 β 2.56 tq (7.5; 2.4 Hz) 33.4 d     H-4a; H-6; H-7 
6   6.83 dd (10.2; 2.4 Hz) 155.1 d C-4a; CH3-5   H-5; H-7; CH3-5 
7   5.92 dd (10.2; 3.0 Hz) 125.1 d     H-5; H-6 
8     199.8 s       
8a     46.6 s       
9  6.28 s 110.9 d C-3a; C-4a; C-8; C-9a   CH3-3 
9a     148.6 s       
3-Me   1.88 d (2.4 Hz) 7.6 q C-2; C-3; C-3a     
5-Me   1.24 d (7.2 Hz) 17.0 q C-4a; C-5; C-6 H-4α H-5 
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3.4 Antiplasmodial activity and cytotoxicity 
 
The crude extract and compounds were screened for in vitro antiplasmodial activity 
against the CQS D10 strain and CQR K1 strain of P. falciparum according to Chapter 
7 (7.6).  The cytotoxicity of samples was also determined against the Chinese hamster 
ovarian (CHO) cell-line according to methods described in Chapter 7 (7.7). 
Cytotoxicity was evaluated to determine the selectivity of the test samples to the test 
organism. 
 
P.falciparum  D10 strain
S.aethiopicus EA extract






IC50 = 2.884 礸/ml














P.falciparum  K1 strain:
S.aethiopicus EA extract




IC50 = 1.406 礸 /ml














P.falciparum  D10 strain
Chloroquine control






















P.falciparum  K1 strain
Chloroquine control























Figure 15 Pooled dose-response curves of S. aethiopicus extract against CQS D10 and 
CQR K1 strains of P. falciparum  
 
The EA extract of S. aethiopicus showed very good in vitro antiplasmodial activity 
against the CQS D10 strain as well as the CQR K1 strain of P. falciparum with IC50-
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Table 4 In vitro antiplasmodial activity and cytotoxicity of the EA extract and isolated 
compounds  







IC50 (µg/ml) CHO/D10 CHO/K1  
S. aethiopicus extract 2.89 ±0.28 1.40d 73.9 ±12.8 25.50 52.79 0.48 
Compound 1 18.13 ±1.56 16.71 ±1.75 >100 ±ND ND ND 0.92 
Compound 2 25.40 ±2.26 5.86 ±0.37 70.5 ±6.31 2.78 12.03 0.23 
Compound 3 3.40 ±0.57 1.75 ±0.33 79.8 ±9.99 23.47 45.60 0.51 
       
Chloroquine 10.87 x 10
-3 ±3.68 146.26 x 10-3 ±30.24    13.45 
Emetine   0.05 ±0.02    
 
IC50-values are given as a mean value with standard deviations of 2 independent experiments 
Selectivity index (SIa) = cytotoxicity IC50/antiplasmodial D10 IC50  
Selectivity index (SIb) = cytotoxicity IC50/antiplasmodial K1 IC50 
Resistance index (RIc) = K1 IC50/D10 IC50 
d = tested on one occasion in duplicate 
ND = not determined 
 
Compound 3 was the most active compound isolated with an IC50-value of 3.4 µg/ml 
against the CQS strain and 1.7 µg/ml against the CQR strain of the parasite (Table 4). 
The RI of compound 2 showed a significant increase in activity towards the CQR K1 
strain. Compound 1 was equipotent against both strains of the parasite. 
 
3.5 Antimycobacterial, antibacterial and antifungal activity 
 
The antibacterial activity of S. aethiopicus has been established in previous studies 
(Stafford et al., 2005). Therefore test samples (fraction and compounds) were 
subjected to additional testing. Methods for activity testing are described in Chapter 7 
(7.9). The liquid-liquid fraction (pH 11 buffer) consisting of a combination of 
compounds 1 – 3 and was tested in a preliminary screen for antimycobacterial activity 
against M. aurum A+. The compounds were tested against a broad spectrum of 
organisms namely M. tuberculosis, Gram positive S. aureus, Gram negative K. 
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Table 5 MIC’s and IC50-value in µg/ml of compounds 1 to 3 against mycobacterium, 
a Gram-positive and –negative bacterium and a fungus   
 
Sample M. tuberculosis M. aurum (IC50) S. aureus K. pneumoniae C. albicans 
Compound 1 250  >250 >250 >250 
Compound 2 250  >250 >250 >250 
Compound 3 250  >250 >250 >250 
Liquid-liquid fraction  385.5    
Rifampicin 2     
Nystatin     1.6 – 3.2 
Ciprafloxacin   0.3 - 0.6 0.078 – 0.15  
 
MIC = Minimum inhibitory concentration  
 
A MIC of 500 µg/ml was determined for the fraction based on visual growth of M. 
aurum A+. A further test was performed to establish an IC50-value. The fraction was 
found to be moderately active against M. aurum with an IC50-value of 385.5 µg/ml 
(Table 5). The antimycobacterial activity of compounds 1, 2 and 3 revealed an MIC-
value of 250 µg/ml against M. tuberculosis. The compounds showed an enhancement 
in activity with purification. The compounds did not show antibacterial or antifungal 




3.6.1 Antiplasmodial activity 
 
The EA extract of S. aethiopicus was active against the CQS and CQR strains of P. 
falciparum. The crude extract was subjected to bioassay-guided fractionation and 
yielded three novel structurally-related furanoterpenoids. Once the peaks of interest 
were identified the primary fractionation process was optimised. Optimisation using 
liquid-liquid separation instead of SPE proved to be simpler and more rapid. The most 
active SPE fractions namely the 50%, 60%, 70% and 80% ACN fractions were more 
active than the isolated compounds. These results indicated that the antiplasmodial 
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supported by a recent study which deduced that the anti-inflammatory activity of S. 
aethiopicus might be due to synergism (Jäger et al., 2005). It is possible for a fraction 
to show significant bioactivity which might not be revealed by a single constituent of 
the fraction (Trease and Evans et al., 1978).   
 
The activity of the EA extract and compound 3 is comparable against both CQS and 
CQR strains of P. falciparum. All compounds showed low cytotoxicity. The SI of 
compound 3 and the crude extract were also similar. The in vitro results suggest that 
the activity of the crude extract is attributable to compound 3. However the 
synergistic effect of different components could not be ruled out due to the activity of 
the SPE fractions. Compound 3 was the most active against both CQS and CQR 
strains of the parasite but was considered moderately active. Compounds 1 and 2 
showed low activity against P. falciparum. Interestingly, the test samples were more 
selective towards the CQR strain than the CQS strain. This class of compounds is 
unlike current antimalarial drugs which makes it an attractive candidate for chemical 
modifications.  
 
3.6.2 Antimycobacterial, antibacterial and antifungal activity 
 
S. aethiopicus has shown activity against B. subtilis, S. aureus, E. coli and K. 
pneumoniae with activities ranging from 1.56 mg/ml to 3.13 mg/ml (Stafford et al., 
2005). Based on these promising results additional antimycobacterial, antibacterial 
and antifungal testing was performed with a fraction and isolated compounds. The 
semi-pure fraction consisting of all three compounds was extracted using a pH 11 
buffer. The fraction showed moderate activity against M .aurum.  Screening against 
M. aurum serves as a preliminary screen for M. tuberculosis. Thus the isolated 
compounds were subjected to in vitro testing against M. tuberculosis, S. aureus, K. 
pneumoniae and C. albicans. The isolated compounds showed an MIC-value of 250 
µg/ml against M. tuberculosis. The compounds did not show antibacterial or 
antifungal activity at 250 µg/ml. The fraction and isolated compounds were more 
active than the published results for the crude extract. However no significant activity 
was found with the isolated compounds against M. tuberculosis, S. aureus, K. 





































4. In vivo study of S. aethiopicus 
 
The EA extract of the rhizomes of S. aethiopicus showed very promising in vitro 
activity against both CQS and CQR strains of P. falciparum (Table 4). The in vitro 
results revealed that the crude extract and isolated compounds were more selective 
towards the CQR strain than the CQS strain of the parasite. No in vitro cytotoxicity 
was observed with the EA extract and isolates. These interesting results lead to the 
investigation of S. aethiopicus for in vivo antiplasmodial activity, bioavailability and 
metabolism. 
 
4.1 Antiplasmodial testing 
 
 
4.1.1 Schizontocidal activity 
 
 
The EA extract of S. aethiopicus rhizomes was tested in a malaria mouse-model 
according to methods described in Chapter 7 (7.10).  The increased selectivity 
observed towards the CQR strain in vitro resulted in the selection of the CQR P. yeolii 
NS strain for in vivo testing. The EA extract and compound tested dissolved well in 
the preparations used and were administered by gavage. The controls for the vehicles 
used for dose preparation had no effect on parasitemia (Fig 16).  
 
Controls for dose preparation
























Figure 16 Solvent controls against the CQR P. yeolii NS strain using the 4-day 














A four-day (4-D) suppressive test was performed with the EA extract at a dose of 400 
mg/kg bodyweight (bw) dissolved in 5% sodium bicarbonate (SB). The test animals 
were grouped into three groups of three. 
 
Four-day suppressive test










CQ: 15 mg/kg bw














Figure 17 EA extract against CQR P. yeolii NS strain using the 4-day suppressive test 
 
The study showed that the crude extract suppressed the parasitemia during treatment 
(Fig 17). The parasitemia rapidly increased after termination of treatment on day 4 
and was comparative to the untreated control on day 7. The crude extract inhibited 
parasite growth by 65% on day 4 (Table 6). A decline in weight was observed over 9 
days (Table 7).  
 
Table 6 EA extract: Percentage growth inhibition against P. yeolii NS strain using the 
4-day suppressive test 
 
Days post-infection S. aethiopicus (EA) CQ control 
3 40.51% 45.64% 
















Table 7 EA extract: Average weights of mice using the 4-day suppressive test against 
CQR P. yeolii NS strain (±SD) 
 
Days post-infection Untreated control CQ control S. aethiopicus (EA) 
0 26.64 ±2.31 24.36 ±1.13 26.86 ±0.18 
1 26.74 ±2.64 24.38 ±0.89 26.71 ±0.30 
3 26.71 ±1.81 24.08 ±1.30 25.97 ±0.40 
4 26.26 ±2.47 25.17 ±1.46 26.73 ±0.27 
7 21.39 ±3.91 23.87 ±0.49 23.48 ±1.47 
9  22.10 ±0.82 20.36 ±0.82 
 
The results prompted the investigation of the EA extract in a seven-day (7-D) 
suppressive test. The 7-D suppressive test was performed with the EA extract 
administered at 400 mg/kg bw which was dissolved in either 5% SB (with addition of 
5% ethanol) or the lipid-based self-microemulsifying drug delivery system 
(SMEDDS) formulation (Table 8). The SMEDDS formulation consists of the test 
sample, lipids, surfactants and cosurfactants which forms a fine microemulsion of oil-
in-water when exposed to an aqueous environment like the gastrointestinal tract (Wu 
et al., 2006). For optimal solubility in the SMEDDS formulation the test samples were 
first dissolved in ethanol then ethyl linoleate and lastly tween 80 was added. The 
addition of ethanol to 5% SB solution resulted in better solubility of the EA extract. 
The test animals were grouped into two groups of three for controls (untreated and 
CQ). The two groups receiving the EA extract consisted of four mice each.  
 
Table 8 Composition of SMEDDS formulation 
 
Drug / excipient Composition 
Test sample 55.5 (8.55%) 
Ethanol 59.4 (9.15%) 
Tween 80 356.4 (54.9%) 
Ethyl linoleate 178.2 (27.4%) 
 
Percentage composition in parenthesis 
 
The importance of drug formulation in the evaluation of in vivo antimalarial activity 














bioavailability and pharmacokinetics must be taken into consideration when selecting 
a drug formulation. Hence the activity of the crude extract was evaluated in a lipid-
based and aqueous formulation. The crude extract preparation in the SMEDDS 
formulation had no effect on suppressing parasitemia (Fig 18). These observations are 
probably due to the progression of the disease. The parasitemia of this group was also 
higher than the untreated control group on day 5 but remained steady until day 7. The 
5% SB formulation showed suppression of parasitemia on day 4 and 7 of treatment. 
The schizontocidal activity of S. aethiopicus EA extract showed that the 5% SB 
formulation is more effective than the SMEDDS formulation. The SMEDDS 
formulation group appeared very sick on day 7 and had a steady weight loss (Table 9). 
 
Seven-day suppressive test









CQ: 15 mg/kg bw















Figure 18 EA extract against CQR P. yeolii NS strain using the 7-day suppressive test  
 
Table 9 EA extract: Average weights of mice using the 7-day suppressive test against 
CQR P. yeolii NS strain (±SD) 
 
   S. aethiopicus (EA) 
Days post-infection Untreated control CQ control Sodium bicarbonate SMEDDS 
     
0 25.40 ±0.76 22.86 ±2.82 25.79 ±1.97 22.01 ±1.11 
4 23.73 ±0.37 21.32 ±2.58 23.75 ±2.33 19.54 ±2.19 
6 22.30 ±0.52 22.43 ±2.38 22.54 ±2.61 17.30 ±1.27 















Compound 3 was the most active compound isolated from the EA extract with an 
IC50-value of 3.4 µg/ml against the CQS D10 strain of P. falciparum (Table 4). 
Compound 3 was prepared in 10% dimethylsulphoxide (DMSO) which was 
established as the optimal formulation based on solubility. The compound was tested 
at 100 mg/kg bw using the 4-D suppressive test. Limited material allowed for testing 
at only one concentration. The test animals were divided into three groups with four 
mice in the untreated control group, three in the CQ control group and five in the 
group for the test compound. 
 
Four-day suppressive test


















Figure 19 Compound 3: Average parasitemia on day 4 against CQR P. yeolii NS 
strain (Control = untreated) 
 
Table 10 Compound 3: Percentage growth inhibition against P. yeolii NS strain on 
day 4 
 % Growth inhibition 
Compound 3 23.18 
CQ 79.45 
 
Compound 3 showed suppression of parasitemia on day 4 of treatment (Fig 19). The 
evaluation of the growth inhibition showed that the compound inhibited 23.2% of 
parasite growth on day 4 (Table 10). The compound showed minimal suppression of 














significantly from day 4 to 7 for the untreated control and test compound group which 
indicated the severity of the disease state (Fig 20). 
 
Weights of mice


















Figure 20 Compound 3: Average weights of mice using the 4-day suppressive test 
against the CQR P. yeolii NS strain 
 
4.1.2 Parasite clearance and prophylactic tests 
 
The therapeutic effect of S. aethiopicus was evaluated in a parasite clearance and 
prophylactic experiment. The study design of the parasite clearance and prophylactic 
tests either started treatment four days after infection or four days before infection, 
respectively. The crude extract was administered by gavage at 400 mg/kg bw and 800 
mg/kg bw. The extract was dissolved in 5% SB to which 5% ethanol was added. Tests 
were performed against the CQR P. yeolii NS strain. 
 
4.1.2.1 Parasite clearance test 
 
The parasite clearance experiment was performed according to methods in Chapter 7 
(7.10.4). A four day treatment schedule was started on day 4 post-infection 



























CQ: 15 mg/kg bw
Extract: 400 mg/kg bw














Figure 21Clearance test: Average parasitemia on day 4 and 7 against CQR P. yeolii 
NS strain  
 
No parasite clearance effect was observed after four days of treatment with the crude 
extract compared to the untreated control (Fig 21). A two-fold increase in dose did not 
show a dose-related response to treatment. The parasitemia of the CQ control 
remained unchanged at the dose treated. The steady decline in weights indicated that 
the disease increased in severity (Table 11). 
 
Table 11 Averaged weights of mice in the parasite clearance test against CQR P. 
yeolii NS strain (±SD) 
   S. aethiopicus EA extract 
Days post-infection Untreated control CQ control 400 mg/kg bw 800 mg/kg bw 
0 25.21 ±2.21 24.92 ±1.96 24.78 ±1.63 24.31 ±3.24 
3 24.64 ±2.44 24.24 ±1.99 24.23 ±1.80 23.64 ±2.82 
7 21.79 ±1.67 25.13 ±2.24 21.80 ±1.34 19.89 ±0.85 
10 19.46 ±0.89 24.82 ±2.68 19.69 ±1.67 18.44 ±1.77 
12  24.08 ±3.10 18.83 ±1.36 17.82 ±1.59 
 
4.1.2.2 Prophylactic test 
 
The method for the prophylactic test was according to Chapter 7 (7.10.5). Test 
animals were treated for four consecutive days prior to infection and treatment was 



























Extract: 400 mg/kg bw
Extract: 800 mg/kg bw














Figure 22 Prophylactic test: Average parasitemia on day 4 and 7 against CQR P. 
yeolii NS strain  
 
Table 12 Averaged weights of mice in the prophylactic test against CQR P. yeolii NS 
strain (±SD) 
 
   S. aethiopicus 
Days post-infection 
Untreated 
control CQ control 400 mg/kg bw 800 mg/kg bw 
day 4 of treatment 25.39 ±1.56 27.50 ±0.84 27.30 ±0.72 27.16 ±1.27 
0 25.21 ±2.21 27.35 ±1.19 26.50 ±1.13 26.29 ±1.05 
3 24.64 ±2.44 25.90 ±1.48 25.58 ±0.45 25.83 ±0.97 
7 21.79 ±1.67 23.76 ±1.22 23.19 ±1.70 23.33 ±1.85 
10 19.46 ±0.89 _ 20.00 ±1.16 20.50 ±1.37 
12 _ _ 20.47 ±1.37 20.80 ±0.28 
 
The investigation of S. aethiopicus for prophylactic properties did not reveal very 
promising results (Fig 22 and Table 12). A slight decrease in parasite growth was 
observed on the day 4 and 7 of treatment with the crude extract. The results were 
comparable for both doses tested. The CQ control showed a prophylactic effect on 



















4.2 Bioavailability study of compound 3 
 
A novel furanoterpenoid namely compound 3 showed promising in vitro activity 
against the malaria parasite but was not active in vivo. Interestingly the EA extract 
showed promising antiplasmodial activity in both in vitro and in vivo tests. The lack 
of in vivo efficacy of compound 3 prompted a pharmacokinetic study. 
Pharmacokinetic factors such as ADME can be evaluated in an in vivo model.  Two 
studies were designed to understand the pharmacokinetics of compound 3 using a 
mouse-model. The absence of in vivo efficacy of compound 3 may be a result of poor 
absorption or metabolism to inactive compounds. The first study investigated the 
bioavailability of compound 3 alone or in combination as a constituent of the EA 
extract. Studies have shown that the route of administration and drug formulation are 
important parameters in accessing bioavailability and consequently in vivo activity 
(Peters et al., 2002). Therefore these parameters were investigated in this preliminary 
pharmacokinetic investigation. The second study investigated the in vivo metabolism 
of compound 3. 
 
Hyphenated mass spectrometry (LC-MS/MS) based assays have largely replaced 
bioanalytical methods such as HPLC, gas-chromatography (GC) and GC-MS due to 
its rapid throughput and increased sensitivity (Shah et al., 2000). LC-MS/MS 
technology has become the preferred method of analyses. Parameters such as 
selectivity, sensitivity, recovery, accuracy and stability are imperative for method 
validation (Bansal et al., 2007). Several of these parameters were adhere to during 
method development. Most in vivo pharmacokinetic experiments use a large sample 
size which often requires that the test animals are sacrificed at each time-point. The 
method developed during this study evaluated bioavailability using one animal for all 
time-points. This eliminates intervariability between different animals and limits the 
amount of animals used. A washout period of 2 – 3 weeks was used to allow for the 


















4.2.1 Mass spectrometry method development 
 
A preliminary investigation of the bioavailability of compound 3 in a mouse-model 
was performed using LC-MS/MS technology. An API 3200 triple quadrupole mass 
spectrometer (LC-MS/MS, Applied Biosystems) with ESI positive ionization with 
multi-reaction monitoring (MRM) was used for analyses. The mobile phase (MP) 
used was ACN:0.1% formic acid (6:4) with a 5 µl infusion. The protonated molecular 
ion [M+H]+ at 245 (Fig 23) correlated with the high resolution MS data presented in 
Appendix II.  
 
 +Q1: 0.396 min from Sample 1 (TuneSampleID) of MT20070118165429.wiff (Turbo Spray) Max. 3.5e6 cps.

































384.0 434.8422.4233.5 262.7135.5 288.7191.6 370.3352.7 489.4471.8
79.5 85.2 301.5 409.7 443.2214.5 259.3 322.0250.5 375.7171.0157.1 279.6 425.7381.6186.6114.3 485.1142.6 349.5
 
Figure 23 Mass spectrum of compound 3, molecular ion [M+H]+ at 245 
 
The molecular ions were selected in the first mass filter and fragmented in the 
collision cell to form product ions (Fig 24).  The most abundant product ion [M+H]+ 














 +MS2 (245.25) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of P3 WG_InitProduct_Pos.wiff (Turbo Spray) Max. 1.0e6 cps.






































141.264.8 77.2 128.2105.239.2 198.841.0 164.8 171.055.0 157.2 181.289.2 143.2 203.2119.2 227.057.2 75.4 107.469.229.2 212.293.4 125.881.026.8 229.8
 
Figure 24 Product ion mass spectrum of molecular ion [M+H]+ at 245 
 
4.2.2 Optimization of mass spectrometry 
 
A more sensitive detection method was needed to study the bioavailability of 
compounds. Therefore a pilot study was set-up to evaluate compound 3 extracted with 
a range of pH buffers and compared its absorption in different matrixes. An Applied 
Biosystems 3200 Q-trap mass spectrometer coupled to a high performance liquid 
chromatography system was used to analyse the samples. The MP used was 
ACN:0.1% formic acid (6:4) which was run isocratically for 1.5 min. The molecular 
ion of compound 3 (m/z 244.2) and the major product ion of m/z 116.3 were selected. 
Methods were according to Chapter 7 (7.11.2). Protein precipitation was unsuccessful 
as an extraction method. Liquid-liquid extraction was investigated as an extraction 
method. pH buffers ranging from pH 2 – 12 were prepared with Britton Robinson 
universal buffers (7.3.2).  The liquid-liquid extraction used 10 µl of spiked whole 
blood (10 µg/ml) which was extracted with the respective pH buffers and EA. Extract 





































Figure 25 Extraction of compound 3 using pH buffers 
 
The optimal absorption matrix of compound 3 as evaluated in plasma and red blood 
cells (RBC’s). Absorption of compound 3 in plasma was increased ten-fold compared 
to RBC’s (Table 13). Therefore plasma was used for further analysis as oppose to 
whole blood or RBC’s. 
 
Table 13 Percentage recovery of compound 3 
Sample % Recovery 
RBC 1.93 ±0.03 
Plasma 11.82 ±0.57 
 
4.2.3 Evaluation of method 
 
A preliminary study to evaluate the sensitivity, selectivity, accuracy and 
reproducibility of the LC-MS/MS method was conducted. Only 10 µl of plasma was 
used to spike MP which was serially diluted two-fold in MP from 10 µg/ml to 0.15 
µg/ml.  The LC-MS/MS method was sensitive and selective to compound 3 with a 
lower limit of quantification (LLQ) of 0.156 µg/ml. Examples of the recovery and 





























Std in MP (10 ug/ml) 1570000 N/A No Intercept N/A 
blank 44.5 N/A 0.0234 N/A 
blank 30.4 N/A 0.0226 N/A 
Plasma – 10 ug/ml 155000 10 10.4 104 
Plasma –10 ug/ml 143000 10 9.42 94.2 
Plasma – 5 ug/ml 79700 5 4.91 98.2 
Plasma – 5 ug/ml 88900 5 5.53 111 
Plasma – 2.5 ug/ml 37100 2.5 2.21 88.2 
Plasma – 2.5 ug/ml 44200 2.5 2.64 106 
Plasma – 1.25 ug/ml 21300 1.25 1.26 101 
Plasma – 1.25 ug/ml 20200 1.25 1.2 95.7 
Plasma – 0.625 ug/ml 10000 0.625 0.597 95.6 
Plasma – 0.625 ug/ml 10000 0.625 0.598 95.8 
Plasma – 0.313 ug/ml 4940 0.313 0.304 97.2 
Plasma – 0.313 ug/ml 4900 0.313 0.302 96.5 
Plasma – 0.156 ug/ml 2540 0.156 0.166 106 
Plasma – 0.156 ug/ml 2670 0.156 0.174 111 
 
Std in MP = standard in mobile phase (acetonitrile:0.1% formic acid) (6:4) 
N/A = not applicable 
 
 
20062007.rdb (Compound 3): "Quadratic" Regression ("1 / x" weighting): y = 1.84e+003 x^2 + 1.45e+005 x + -8.64e+003 (r = 0.9991)














































Sample Name: "10"    Sample ID: ""    File: "1001.wiff"
Peak Name: "Compound 3"    Mass(es): "245.2/117.3 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:      10.0    ug/mL  
Calculated Conc:    10.0    ug/mL  
Acq. Date:       3/20/2007  
Acq. Time:       4:30:29 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    4.25   cps
Area Threshold:   21.25   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        1.24   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:     1.23   min
Area:         195000.   counts
Height:          44000.  cps
Start Time:         1.06   min
End Time:           1.37   min



























































Figure 27 Chromatogram of compound 3 at the highest concentration (10 µg/ml) 
 
Sample Name: "STD 0.156"    Sample ID: ""    File: "1016.wiff"
Peak Name: "Compound 3"    Mass(es): "245.2/117.3 amu"
Comment: ""    Annotation: ""
Sample Index:       2     
Sample Type:     Standard  
Concentration:     0.156    ug/mL  
Calculated Conc:   0.167    ug/mL  
Acq. Date:       6/20/2007  
Acq. Time:       2:38:27 PM  
 
Modified:           Yes   
RT Window:         30.0    sec
Expected RT:        1.15   min
Use Relative RT:    No    
 
Int. Type:        Manual  
Retention Time:     1.15   min
Area:          15500.   counts
Height:           2660.  cps
Start Time:         1.05   min
End Time:           1.32   min







































































0.480.37 0.56 1.460.610.41 1.010.11 0.84 0.860.16 0.90 0.95
 
Figure 28 Chromatogram of compound 3 at the lowest concentration (0.15 µg/ml) 
 



















4.2.4 Effect of route of administration and formulation on 
bioavailability  
 
4.2.4.1 Experimental conditions 
 
An Applied Biosystems 3200 Q-trap mass spectrometer coupled to a high 
performance liquid chromatography system was used for analyses.  The MP of 
ACN:0.1% formic acid (6:4) was run isocratically for 1.5 min. The molecular ion of 
compound 3 (m/z 244.2) and the major product ion of m/z 116.3 was selected in the 
positive ion mode, MRM. Methods were as described in Chapter 7 (7.11.3). Stock 
solutions of standard controls were prepared in plasma to known concentrations (10 
µg/ml to 1.5 µg/ml). Standard controls were run at the start and at the end of each 
analysis to monitor the instrument and method. 
 
Absorption of compound 3 was evaluated by comparing the route of administration, 
oral vs. subcutaneous, and drug-formulation. In the first experiment compound 3 was 
prepared at 100 mg/kg bw in 10% DMSO and administered orally and 
subcutaneously. For the second experiment compound 3 was prepared at 100 mg/kg 
bw in a lipid-based SMEDDS formulation and administered orally and 
subcutaneously. The SMEDDS formulation was prepared according to Table 8. Blood 
samples were collected at various time intervals (Table 15). 
 
Table 15 Time intervals of blood sampling 
 
Interval Time 
T0 = blank Before dosing 
T1 30 min after dose 
T2 1 hr after dose 
T3 2 hrs after dose 




















The results were captured below LLQ and were not considered accurate. However a 
trend in absorption was observed. 
 
DMSO formulation


















































Figure 29 Relative concentrations of compound 3 dissolved in 10% DMSO or 
SMEDDS formulation administered either subcutaneously or orally 
 
The results indicated an increased absorption of compound 3 in the SMEDDS 
formulation compared to the DMSO formulation (Fig 29). The estimated absorption 
concentrations at 30 min were 0.05 – 0.075 µg/ml for the SMEDDS formulation and 
0.025 – 0.05 µg/ml for the DMSO formulation. The subcutaneous (SC) route of 
administration achieved higher concentrations after 30 min compared to oral 
administration. The concentration of the SC administration gradually decreased in 2 
hrs and was detected for a further 3 hrs. The DMSO formulation resulted in very low 






















4.3 Bioavailability of the ethyl acetate extract of S. aethiopicus 
 
4.3.1 Mass spectrometry conditions 
 
An Applied Biosystems 3200 Q-trap mass spectrometer in ESI positive ionization 
(MRM) was used for analyses coupled to a high performance liquid chromatography 
system.  The MP of ACN:0.1% formic acid (6:4) was run isocratically for 1.5 min. 
The molecular ion of compounds 1 (m/z 262.1 and major product ion m/z 202.3), 2 
(m/z 246.1 and major product ion m/z 200.2) and 3 (m/z 244.2 and major product ion 
m/z 116.3) were analysed. The LC-MS spectra of compound 1 (Fig 30), compound 2 
(Fig 31) and compound 3 (Fig 23 and Fig 24) correlated with the high resolution data 
presented in Appendix II. 
 
Stock solutions of standard controls of compound 1, 2 and 3 were prepared in plasma 
to known concentrations (10 µg/ml to 1.5 µg/ml). Standard controls were run at the 
start and at the end of each analysis to monitor the instrument and method. The EA 
extract was orally administered at 400 mg/kg bw and 800 mg/kg bw in the SMEDDS 
formulation (Table 8). Blood samples were collected at various time intervals (Table 


















 +Q1: 0.169 min from Sample 1 (TuneSampleID) of MT20061207103216.wiff (Turbo Spray) Max. 1.4e5 cps.

















































 +MS2 (263.17) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of P1WG_InitProduct_Pos.wiff (Turbo Spray) Max. 2.7e5 cps.























































216.879.2 95.2 131.0117.2 152.850.8 138.8 201.0
158.4 189.053.2 69.0 96.8 212.2168.845.0 83.0
196.629.0 113.2 124.881.0 84.8 221.4137.0 225.698.826.6
 
 
Figure 30 Mass spectrum of compound 1, molecular ion [M+H]+ at 263 and product 














 +Q1: 0.404 min from Sample 1 (TuneSampleID) of MT20070118162901.wiff (Turbo Spray) Max. 1.7e6 cps.



































100.579.4 132.3 350.5213.2 230.7 484.2
389.5246.6 285.5 307.4 405.3314.3145.4106.5 121.5 474.5183.6 409.3258.5 384.0337.4209.6 472.4453.568.9 237.463.3 73.2 273.293.5
 
 +MS2 (247.23) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of P2 WG_InitProduct_Pos.wiff (Turbo Spray) Max. 1.3e6 cps.


















































55.2 65.241.2 105.0 168.4 187.0 211.239.2 155.4
173.2103.283.279.2 95.053.2 89.0 167.4147.245.0 63.2 130.0111.4 196.0126.0 133.429.2 205.2181.2150.2101.0 214.027.2 74.4 86.8 227.2
 
 
Figure 31 Mass spectrum of compound 2, molecular ion [M+H]+ at 247 and product 























Dose: 400 mg/kg bw


























Dose: 800 mg/kg bw


























Figure 32 Detection of compounds 1 – 3 after oral administration of S. aethiopicus in 
SMEDDS formulation  
 
Bioavailability data showed that compound 1 was absorbed in greater quantities than 
the other compounds at most time intervals but decreased steadily over the 5hr time 
period (Fig 32). Compound 1 was the major component in the EA extract (Fig 33). 
Compound 2 was absorbed in very low amounts. All three isolates were absorbed 
after 30 min. The plasma levels of compounds increased with an increase of dose. 
Compound 3 was detected at lower levels than compound 1 except at 5 hrs (400 
mg/kg bw). Compound 3 showed a decrease in absorption from 0.5 – 2 hrs but 
increased again at 5hrs. The estimated concentration of compound 3 was 0.6 µg/ml at 
30 min and 5hrs.   
 
 
Figure 33 HPLC profile of EA extract on a C18 RP column (λ = 254 nm) 
Mobile phase H2O:ACN using a gradient of 10 – 100% ACN (20 min), 100% ACN 
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4.4 Metabolism study of compound 3 
 
The second study was designed to investigate the effect of metabolism on in vivo 
schizontocidal activity of compound 3. The purpose of this study was to detect 
possible metabolites in order to determine if the low plasma levels of compound 3 
observed in the bioavailability study is due to metabolism. The metabolism of drugs 
can lead to the production of active or inactive metabolites (Peters et al., 2002). 
Metabolite studies attempt to create an understanding of the mechanism of action of a 
drug.  
 
A systematic approach to metabolite identification and characterization can be 
followed. The identification of metabolites is a time-consuming and complex task 
requiring expertise, instrumental techniques and software applications. The first step 
in metabolite identification is Tandem MS experiments which includes precursor ion 
and neutral-loss scans (Clarke et al., 2001). These experiments are followed by LC-
MS/MS experiments and accurate mass measurement which can result in the 
empirical formula of the novel metabolite. Common metabolite alterations can be 
predicted based on the structure of the drug. Thus a targeted approach for the 
expected metabolites can assist in the identification process. Precursor ion scans is 
used for the detection of novel unexpected metabolites produced by less-common 
metabolic pathways. Precursor ion scans can be conducted with limited knowledge of 
the metabolite’s structure. The fragmentation pattern is used to determine if the 
metabolite contain unaltered fragments of the parent molecule. The bioavailability 
study of compound 3 prompted the next phase of the project which was to search for 
metabolites using precursor ion experiments.  
 
4.4.1 Mass spectrometry conditions for precursor experiment 
 
An Applied Biosystems 3200 Q-trap mass spectrometer coupled to a high 
performance liquid chromatography system using a Phenomenex C18 (15 cm x 4.6 
mm, 5 µm) column with an injection volume of 5 µl. The MP was ACN:0.1% formic 
acid (6:4) and isocratic run rate of 15 min. LC-MS/MS analyses for the metabolite 
study were performed in the positive ion mode (MRM). The LC-MS/MS was set in 














m/z 116.  A precursor ion screen scanned for metabolites with a similar fragmentation 
pattern as compound 3. Q1 was set to scan for large range of possible metabolites 400 
to 900.  The experimental conditions used for precursor ion scan analysis were 
according to Chapter 7 (7.11.5.1).  
 
4.4.2 Sample preparation 
 
The activity of compound 3 was assessed in the blood stage of the parasite life-cycle. 
The extraction method developed for the metabolite study was not as selective as the 
bioavailability study. The liquid-liquid extraction method used for the bioavailability 
study would not extract all possible metabolites. Whole blood as opposed to plasma 
was used for this study in order to extract metabolites that might be present 
intracellularly. Urine and faeces are common elimination matrixes and were also 
investigated for metabolites. Extraction methods were according to methods in 
Chapter 7 (7.11.5.2). The test animal received 100 mg/kg bw of compound 3 in the 
SMEDDS formulation which was administered by gavage. The samples were 
collected at 30 min, 1 hr and 2 hrs time intervals. All test samples, except the blank, 
were pooled before being processed. This allowed for the detection of all metabolites 
over the two hour period. The same sample stocks were used for all LC-MS/MS 
analyses. Compound 3 had a retention time of 7.5 min (Fig 34).   
 
XIC of +MRM (1 pair): 245.2/117.3 amu from Sample 1 (std) of 1002.wiff (Turbo Spray) Max. 3.2e5 cps.
















































The total ion chromatograms of the blank sample and test samples (blood, urine and 
faeces) were evaluated.  The presence of compound 3 as well as metabolites was 
assessed by comparing the test sample to a blank control. Compound 3 was not 
present in the blood, urine or faeces and no significant differences between the test 
sample and the blank control were observed (Fig 35). Arrows indicate the retention 
time of compound 3. 
 
TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 9.8e7 cps.

















































TIC of +Q1: from Sample 1 (urine sample) of 1008.wiff (Turbo Spray) Max. 1.0e8 cps.





































6.03 11.012.85 5.36 8.025.174.76 7.27 11.344.18 9.898.46 9.20 11.90
 
TIC of +Q1: from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 5.8e7 cps.





































7.05 13.161.32 11.257.265.20 5.94 10.971.85 5.054.52 10.103.17 3.67 6.42 9.938.65 11.84
12.40
 
Figure 35 Comparison of total ion chromatograms for blank sample (red) to test 

















The precursor experiment was done to evaluate the presence of the product ion m/z 
116.3 in the test samples. Possible metabolites of compound 3 which have the same 
major product ion should be detected using this method. These results did not reveal 
any visible difference between the test samples and the blank controls (Fig 36). 
Arrows indicate the retention time of compound 3. 
 
TIC of +Prec (117.30): from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 1.6e5 cps.





































TIC of +Prec (117.30): from Sample 1 (urine sample) of 1008.wiff (Turbo Spray) Max. 5.4e4 cps.








































TIC of +Prec (117.30): from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 7.4e4 cps.












































Figure 36 Comparison of total ion chromatograms for blank sample (red) to test 

















4.5 Discussion  
 
4.5.1 Schizontocidal activity 
 
The EA extract and compound 3 showed promising in vitro activity particularly 
against the CQR strain of P. falciparum. Therefore these two samples were tested for 
in vivo activity against the CQR P. yeolli NS strain. The EA extract inhibited parasite 
growth by greater than 50% on day 4 of the 4-D test. A rapid increase in parasitemia 
was observed after termination of treatment. Compound 3 suppressed the parasitemia 
(growth inhibition less than 50%) on day 4 of the 4-D test. The schizontocidal activity 
of the crude and compound 3 were not comparable based on the growth inhibition. 
These results indicated that the antiplasmodial activity of the EA extract might be due 
to synergism.  
 
The schizontocidal activity of the EA extract using the 4-D suppressive test led to 
evaluation using a 7-D suppressive test. Two drug formulations, an aqueous-based 5% 
SB (with addition of 5% ethanol) and lipid-based SMEDDS formulation of the EA 
extract were compared at the same dose in the 7-D test. The evaluation of in vivo 
antimalarial activity by comparing drug formulations has shown to be useful in pre-
clinical drug development (Peters et al., 2002). The SMEDDS formulation was 
inactive while the 5% SB formulation showed suppression of parasitemia on days 4 
and 7. However the parasitemia remained steady from day 5 to 7 with the SMEDDS 
formulation. The EA extract did not have an effect on the clearance of parasitemia. A 
weak to moderate prophylactic effect was observed with the EA extract. Both 
clearance and prophylactic experiments did not show a dose-response to the high or 
lower dose tested.  
 
4.5.2 Bioavailability and metabolism studies 
 
The bioanalytical method developed was highly selective and sensitive for analyzing 
in vivo plasma samples.  A method for the detection of compound 3 in small animals 
was successfully developed using LC-MS/MS technology. Two formulations of 
compound 3 were administered either orally or subcutaneous (SC). The lipid-based 














improving bioavailability by enhancing the solubility of test compounds (Peters et al., 
2002). The absorption values were below the LLQ and could not be considered 
accurate, but were used to show a trend. Interestingly a trend in absorption was 
observed with drug formulations as well as the route of administration. After 30 min 
the estimated absorption concentrations were 0.05 – 0.075 µg/ml for the SMEDDS 
formulation and 0.025 – 0.05 µg/ml for the DMSO formulation. An increase in 
absorption was observed with the lipid-based SMEDDS formulation compared to the 
10% DMSO formulation. With both formulations the estimated concentration after 30 
min was higher for the SC route than the oral administration. SC administration led to 
high initial absorption levels but gradually decreased in 2 hrs remaining steady at low 
levels for 3 hrs. A similar absorption pattern was observed for the SC administration 
using both formulations. Oral administration of the SMEDDS formulation showed an 
increased absorption after 2 hrs than for the SC administration. The oral 
administration of the DMSO formulation reached very low levels in blood. 
Compound 3 is poorly absorbed particularly when administered orally with the 
DMSO formulation. The plasma levels are three times less than the required in vitro 
IC50-value. The efficacy testing was performed using an oral administration of 
compound 3 in the DMSO formulation. Therefore poor absorption could account for 
its weak in vivo activity. 
 
The three isolated compounds (1 – 3) of S. aethiopicus were evaluated in the 
bioavailability investigation of the EA extract. Oral administration of the EA extract 
at 400 mg/kg bw and 800 mg/kg bw (SMEDDS formulation) revealed that compound 
1 was the most absorbed compound. HPLC data showed that compound 1 is the major 
peak in the crude extract. The abundance of compound 1 in the crude extract can 
account for the relatively high plasma levels of this compound. Dose-dependant 
increases in absorption levels were observed with all three compounds. Compound 1 
was eliminated or metabolized within 5 hrs as evident by the steady decrease in 
absorption. Compound 2 was absorbed in very low amounts compared to compounds 
1 and 3. Compound 3 was absorbed from the EA extract at lower levels than 
compound 1 except for results at 5 hrs. A trend in the absorption of compound 3 was 
observed at both high (800 mg/kg) and low doses (400 mg/kg) of the EA extract. This 














reach the same level as for the 30 min time interval. This phenomenon was also 
observed when the compound was orally administered in the SMEDDS formulation 
as a single entity. Thus compound 3 might have a delayed absorption or slow release 
in the SMEDDS formulation. The plasma levels of compound 3 when given as a 
crude extract is 10-fold higher compared to plasma levels if given alone. The 
increased absorption of compound 3 when given as an EA extract might explain the in 
vivo activity of the extract. However the EA extract was administered at a dose four 
times higher than the pure compound. The difference in concentration might account 
for the observed plasma levels. Studies on ART have shown that congener 
constituents within a plant preparation can assist in its solubility and enhance activity 
(Bilia et al., 2002). The combination of compounds present in the EA extract might 
assist in the solubility, stability and absorption, and ultimately enhance activity of 
compound 3.  
 
A preliminary metabolism study of compound 3 (SMEDDS formulation) was 
performed by oral administration. The study period was limited to two hours. The 
results did not detect a significant difference between the test samples (blood, urine 
and faeces) and blank control. The compound might be metabolized in a shorter 
period of time or the metabolites can be unstable. Compound 3 showed an increase in 
absorption after two hours thus it is possible that an extended collection time might 
reveal its detection in the metabolism study. Metabolites of compound 3 should have 
the same fragmentation pattern. The precursor experiment was conducted to evaluate 
the presence of the major product ion.  The expected fragmentation was not observed 
with this experiment. The metabolite search was limited and more intense 
investigation might reveal metabolites. The absence of compound 3 indicates that this 
compound undergoes phase I metabolism and is probably a substrate of CYP 
enzymes. The results indicate that the lack of in vivo activity of compound 3 is due to 








































A. ferox leaves were initially collected in summer and winter (flowering season) at 
Kirstenbosch botanical gardens and subsequently collected at Albertinia during winter 
(South Africa). A. ferox was investigated for novel antiplasmodial compounds using 
the following chromatographic techniques: SPE, column chromatography, thin layer 
chromatography (TLC), HPLC and a chromatotron. In vitro and in vivo bioactivity 
testing was performed according to the methods described in Chapter 7. Additional in 
vitro tests were performed against M. aurum A+. The crude extract was tested for in 
vivo antiplasmodial activity using a malaria mouse-model.  
 
5.2 Bioassay-guided fractionation 
 
5.2.1 Activity testing of crude extracts 
 
The whole leaf as well as the leaf separated into the inner gel and outer leaf were 
extracted with different solvent systems (Table 16). 
 
Table 16 Percentage yields of A. ferox extractions 
 
Plant part DCM MeOH DCM:MeOH H2O Leaf exudate 
      
Whole leaf 2.07 13.21 12.78 20.34 71.8 
Inner gel 3.18     
Outer leaf 1.59     
 
DCM = dichloromethane, MeOH = methanol, EA = ethyl acetate, DCM:MeOH (1:1) 
 
The crude extracts were tested for in vitro antiplasmodial activity against the CQS 
D10 strain of P. falciparum. The dichloromethane (DCM) extraction of the whole leaf 

















Table 17 Percentage parasite survival of A. ferox whole leaf extracts using a 3-point 
concentration test against CQS D10 strain of P. falciparum (n = 1) 
 
n = number of experiments in duplicate 
 
Seasonal variation in IC50-values was observed for leaves collected at Kirstenbosch 
botanical gardens (Fig 37). Leaves collected in winter were more active than the 











Summer: IC50 = 22.336 礸/ml








































Figure 37 Pooled dose-response curves of whole leaf extracts (n = 3) and CQ control 
(n = 2) against CQS D10 strain of P. falciparum 
 
Winter collections were preferred based on the observed increase in activity. The 
HPLC profiles of collections in winter at two different locations namely Kirstenbosch 
botanical gardens and Albertinia were compared.  
Extraction solvent % Parasite Survival 
 25 µg/ml 12.5 µg/ml 6.25 µg/ml 
    
DCM 16.99  40.00 60.95 
MeOH 88.93 100.74 105.08 
DCM:MeOH 97.34 91.55 109.70 
H2Oa 103.24  92.39  88.02  
Leaf exudate 104.34 99.12  85.02  
 30 ng/ml 15 ng/ml 7.5 ng/ml 


















































































Figure 38 HPLC profiles and UV spectrum of A. ferox whole leaf DCM extracts on a 
C18 RP column (λ = 300 nm)  
HPLC conditions: Injection: 50 µl injection of a 1mg/ml solution. Mobile phase 
ACN:H2O using a gradient of 10 – 100% ACN (20 min), 100% ACN hold (2 min), 
100 – 10% ACN (3 min), 10% ACN hold  (5 min).  
 
The HPLC profiles of plant extracts from two different locations compared well with 
each other (Fig 38). Several peaks from the Kirstenbosch collection appeared smaller 
when compared to the Albertinia collection indicating that the compound/s are in 
lesser amounts. The peak at retention time 12.1 min does not appear in the 




































Kirstenbosch collection but not in the Albertinia collections. The UV spectral data of 
the peak at 8.1 min observed in both collections corresponds with spectra for aloin-
like compounds. Aloin type spectra reveal major bands at approximately 270 nm, 300 
nm and 360 nm (Zonta et al., 1995). Aloin (Sigma) was analyzed using HPLC under 
the same conditions as the crude extracts (Fig 39). The HPLC analyses showed that 































Figure 39 HPLC profiles and UV spectrum of aloin on a C18 RP column (λ = 300 
nm)  
HPLC conditions: Prepared to 1 mg/ml in DMSO. Mobile phase H2O:ACN using a 
gradient of 10 – 100% ACN (20 min), 100% ACN hold (2 min), 100 – 10% ACN (3 
min), 10% ACN hold  (5 min).  
 
The extracts were tested for in vitro antiplasmodial activity and cytotoxicity (Table 
18). The whole leaf DCM extract was tested against the CQR K1 strain of P. 
falciparum. The results revealed an averaged IC50-value of 47.3 µg/ml against the 
CQR K1 strain of P. falciparum. The antiplasmodial activity of the gel was 
comparable against both strains of the parasite. The outer leaf extract collected at 
Kirstenbosch was more active against the CQR K1 strain than the Albertinia 
collections. The extracts did not show any cytotoxicity against the Chinese Hamster 



























Table 18 IC50-values of A. ferox DCM extracts against CQS D10 strain of P. 
falciparum 
 
Plant part Location Antiplasmodial  Cytotoxicity RIa 
  D10: IC50 (µg/ml) K1: IC50 (µg/ml) CHO: IC50 (µg/ml)  
Whole leaf Kirstenbosch _ 47.30 ±6.67 >100 _ 
Gel Kirstenbosch 20.27 ±2.95 25.30 ±2.97 > 100 1.25 
Outer leaf Kirstenbosch 83.8 ±10.86 62.81b  > 100 0.75 
Gel Albertinia 28.87 ±3.07 35.55 ±0.07 > 100  1.23 
Outer leaf Albertinia >100 >100 >100  
Chloroquine  16.77 ±0.82 269.61 ±113.1 _ _ 
Emetine  _ _ 0.06 _ 
 
IC50-values are given as a mean value with standard deviations of 2 or 3 independent experiments 
Resistance index (RIa) = K1 IC50/D10 IC50 
b = tested on one occasion in duplicate 
 
Several chromatographic techniques were used to fractionate and purify compounds 
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5.2.2 Compound 1 
 
The whole leaf DCM extract was fractionated using SPE (7.4). Activity testing using 
a three-point concentration test revealed that SPE fractions of 60%, 80% and 100% 
ACN are the most active (Table 19). Percentage survival is given as a mean value of 
two independent experiments performed in duplicate (± SD) 
 
Table 19 Percentage parasite survival of A. ferox SPE fractions using a 3-point 
concentration test against CQS D10 strain of P. falciparum 
 
SPE fractions % Parasite Survival 
 25µg/ml 12.5µg/ml 6.25µg/ml 
100% A C N 2.91 ±4.12 7.20 ±1.35 14.86 ±3.75 
80% A C N 5.20 ±3.48 8.15 ±4.02 23.07 ±9.12 
60% A C N 4.53 ±2.94 20.65 ±3.40 27.98 ±4.13 
40% A C Na 21.85 40.83 50.66 
20% A C N 73.80 ±13.41 77.52 ±9.72 75.28 ±11.02 
  30 ng/ml 15 ng/ml 7.5 ng/ml 
CQ 30.60 ±9.54 42.56 ±13.6 68.13 ±14.18 
 
a = tested once in duplicate 
 
SPE was optimized from 20% ACN increments to 5% increments which revealed that 
fractions at 55%, 80%, 85% and 90% ACN were the most active (Fig 40). 
 
SPE fractions against P. falciparum  D10 strain




































Table 20 SPE fractions separated using TLC 
 
SPE Fraction PTLC band 
Number of 
TLC Bands Rf-value 
        
100% ACN 3 3 0.265, 0.296, 0.857 
  4 2 0.298, 0.309 
  5 1 0.301 
  6 2 0.256, 0.280 
  8 4 0.269, 0.289, 0.404, 0.904 
  12  8 0.250, 0.289, 0.519, 0.558, 0.635, 0.692, 0.731, 0.885 
  15  4 0.278, 0.463, 0.556, 0.667 
  17 3 0.260, 0.620, 0.780 
90% ACN 2 3 0.265, 0.286, 0.857 
  3 1 0.277 
  7 3 0.278, 0.704, 0.926 
  8 2 0.220, 0.780  
  9 2 0.220, 0.840 
85% ACN 2 2 0.224, 0.857 
  3 1 0.286 
  4 1 0.265 
  6 3 0.269, 0.596, 0.885 
  8 2 0.278, 0.926 
  10 2 0.220, 0.800  
  11 2 0.220, 0.800 
80% ACN 2 3 0.276, 0.857, 0.979 
  3 1 0.286 
  4 1 0.256 
  5 3 0.250, 0.596, 0.885 
  6 2 0.220, 0.780 
  7 2 0.220, 0.820 
65% ACN 1 2 0.245, 0.878 
  2 1 0.298 
 3 2 0.256, 0.878 
 4 4 0.276, 0.575, 0.701, 0.759 
60% ACN 1 2 0.245, 0.878 
  2 1 0.277 
  3 1 0.247 
 4 4 0.299, 0.598, 0.713, 0.736 
55% ACN 1 2 0.296, 0.420 
  2 3 0.269, 0.423, 0.885 
  3 2 0.220, 0.720 
 4 4 0.264, 0.575, 0.689, 0.747  
50% ACN 1 4 0.209, 0.235, 0.259, 0.321 
  2 3 0.269, 0.442, 0.904 
  3 3 0.264, 0.586, 0.759 
 















TLC separations of SPE fractions led to the isolation of compound 1 which was 
obtained by combining TLC bands with Rf-values of 0.3 (Table 20). Compound 1 
was not detected using HPLC with UV detection therefore it was evaluated using LC-
MS technology. Conditions for LC-MS analysis are described in Chapter 7 (7.11). 
The LC-MS was scanned for possible mass ions from m/z 50 to 500 with a cycle time 
of 0.5 seconds. Compound 1 was infused using a mobile phase (MP) of ACN:0.1% 
formic acid (1:1). LC-MS data revealed that the mass ion of m/z 403.3 with negative 
ionization might be the molecular ion (Fig 41). The chemical structure of this 
compound could not be determined using NMR due to insufficient material. 
 
 -Q1: 0.295 min from Sample 1 (TuneSampleID) of MT20080702133415.wiff (Turbo Spray) Max. 1.1e6 cps.






































83.2 117.162.0 140.996.8 375.1
178.9 241.1 431.2393.1 461.2299.3191.0 206.2128.2 163.3 421.2 488.0265.4101.2 343.0321.2293.1 348.1 377.1153.3
 
 
Figure 41 LC-MS spectrum of compound 1.  




















5.2.3 Compound 2 
 
SPE fractions obtained from the whole leaf DCM extract were also separated using a 
chromatotron (7.4.1). The chromatotron works on the same separation principle as 
TLC. This procedure is not as time consuming as TLC and can be used as a 
preparative method of separation. Therefore the chromatotron was used to optimize 
the fractionation process as an alternative to TLC. However, fractionation using the 
chromatotron method resulted in high yields but poor separation and irreproducibility 
(Table 21). Chromatotron fractions were further purified using preparative thin layer 
chromatography (PTLC) and analytical TLC techniques. The 65% ACN SPE fraction 
was not compatible with the chromatotron method and was separated only using 
PTLC.   
 
Table 21 SPE fractions separated using a chromatotron 
 
SPE fraction Chromatotron fraction Mobile phase % Yield 
60% ACN A Hex:EA (8:2) 15.19 
  B MeOH:EA (1:1) 53.21 
80% ACN  A Hex:EA (8:2) 25.29 
  B MeOH:EA (1:1) 15.99 
  C MeOH 7.99 
  D MeOH:H2O 3.64 
  E MeOH wash 12.22 
85% ACN  A Hex:EA (8:2) 2.26 
  B Hex:EA (8:2) 7.22 
  C MeOH:EA (1:1) 5.89 
  D MeOH:EA (1:1) 16.59 
  E MeOH 14.42 
  F MeOH:H2O 10.61 
90% ACN  A Hex:EA (8:2) 6.73 
  B Hex:EA (8:2) 45.56 
  C MeOH:EA (1:1) 10.04 
  D Between bands 36.21 
  E Waste 2.05 
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Figure 42 Averaged IC50-values of chromatotron fractions obtained from SPE 
fractions against the CQS D10 strain of P. falciparum (n = 2) 
 
An enhancement in activity was observed with fractions obtained from the 
chromatotron (Fig 42). The results showed that for chromatotron band A, the 60% and 
80% ACN SPE fractions were the most active. Chromatotron band B was the most 
active for the 80% and 85% ACN SPE fractions.  Chromatotron band C of the 85% 
ACN SPE fraction showed the most activity. Activity was observed with 
chromatotron band D of the 80% and 90% ACN SPE fractions. Chromatotron bands E 
and F did not show an increase in activity with IC50-values higher than 10.  
 
Further fractionation of active chromatotron bands was performed on PTLC and 
subjected to further activity testing. PTLC bands obtained from chromatotron band A 
of the 80% ACN SPE fraction and band D of the 90% ACN SPE fraction showed 
activity in an initial three-point concentration test (Table 22). Percentage survival is 





















Table 22 Percentage parasite survival of PTLC bands using a 3-point concentration 
test against the CQS D10 strain of P. falciparum  
 
Chromatotron fraction PTLC band % Parasite Survival 
  10 µg/ml 5 µg/ml 2.5 µg/ml 
85% ACN SPE, band B 1 96.86 ±1.19 98.05 ±6.43 105.65 ±11.53 
 2 97.20 ±14.57 91.30 ±4.67 94.65 ±1.48 
 3 95.35 ±2.90 96.55 ±0.07 81.45 ±12.94 
90% ACN SPE, band D 1 16.60 ±17.68 26.40 ±17.54 44.75 ±16.33 
 2 89.15 ±3.32 93.90 ±0.99 84.90 ±0.28 
 3 39.70 ±23.76 67.50 ±10.61 76.25 ±11.67 
 4 29.70 ±14.57 63.20 ±3.68 81.90 ±9.19 
80% ACN SPE, band A 1 8.75 ±8.27 19.35 ±11.67 34.90 ±21.21 
 2 80.40 ±9.90 88.60 ±19.80 87.10 ±11.74 
 3 29.30 ±17.39 52.45 ±12.66 73.15 ±5.73 
 4 97.60 ±15.56 93.05 ±11.24 93.70 ±11.60 
85% ACN SPE, band C 1 87.45 ±6.01 95.90 ±7.35 88.15 ±4.88 
 2 96.10 ±2.69 105.10 ±1.56 93.10 ±4.24 
60% ACN SPE, band A 1 74.70 ±7.64 97.35 ±0.07 96.95 ±3.61 
 2 104.75 ±2.05 95.50 ±0.57 96.35 ±3.46 
  30 ng/ml 15 ng/ml 7.5 ng/ml 
Chloroquine  30.55 ±10.96 64.30 ±7.78 90.75 ±15.34 
 
Mobile phase = Toluene: Ethyl acetate (93:7) 
 
The PTLC bands which showed activity in the three-point concentration test were 
tested in a full dose-response assay to determine their IC50-values (Table 23). Band 1 
of both chromatotron fractions was the most active. 
 
Table 23 IC50-values of active PTLC bands against the CQS D10 strain of P. 
falciparum  
 
Chromatotron fraction PTLC band IC50-value (µg/ml) 
      
80% ACN SPE, band A Band 1 1.30 ±0.28 
 Band 3 8.30 ±0.28 
90% ACN SPE, band D Band 1 2.60 ±0.42 
 Band 3 10.00 ±1.56 
 Band 5 7.30 ±1.70 
 
Mobile phase = Toluene: Ethyl acetate (93:7) 
















Table 24 Chromatotron fractions separated via TLC 
 
Chromatotron fraction PTLC band Number of TLC bands Rf-value 
        
80% ACN SPE, A Band 1 2 0.071, 0.476 
 Band 3 3 0.042, 0.333, 0.370 
90% ACN SPE, D Band 1 2 0.055, 0.436 
 Band 3 3 0.036, 0.333, 0.458 
 Band 5 4 0.071, 0.220, 0.488, 0.625 
 
 
Analytical TLC was used to purify active chromatotron fractions (Table 24). 
Compound 2 was isolated from chromatotron band D of the 90% ACN SPE fraction 
using TLC (Rf-value = 0.22). A band with a RF-value of 0.22 was also found in 
several active SPE fractions separated via TLC (Table 20). This gave an indication 
that this common band might be the compound responsible for the bioactivity. The 








































































Figure 43 HPLC profile and UV spectra of compound 2 on a C18 RP column (λ = 230 
nm)  
HPLC conditions: Mobile phase H2O:ACN using a gradient of 10 – 100% ACN (20 
min), 100% ACN hold (2 min), 100 – 10% ACN (3 min), 10% ACN hold  (5 min).  
 
HPLC analysis of compound 2 revealed that the compound might have decomposed 














43). The UV-spectrum of compound 2 revealed absorbance around 223.9 nm, 261.6 
nm and 364.6 nm. The absorbance data suggests compound 2 has a chromone-like 
structure (Zonta et al., 1995). LC-MS and NMR analyses could not be performed due 
to instability problems. 
 
5.2.4 Compounds 3 and 4 
 
The inner gel was shown to be the plant part consisting of the most active constituents 
(van Wyk et al., 1996). The extractions of the inner gel and outer leaf were not very 
active against the parasite (Table 18).  
 
Table 25 PTLC bands of A. ferox gel and outer leaf extracts  
 
Plant part PTLC band IC50 (µg/ml) 
    
Gel 1 13.75 ±1.91 
 2 6.80 ±0.71 
 3 25.25 ±0.92 
 4 26.30 ±ND 
 5 21.14 ±ND 
 6 >100 ±ND 
Outer leaf 1 8.65 ±1.20 
 2 11.45 ±3.89 
 3 13.40 ±1.56 
 4 17.55 ±1.77 
 5 8.75 ±0.35 
 6 13.35 ±4.74 
 7 2.85 ±0.21 
 8 6.25 ±0.92 
 9 6.90 ±2.40 
   
 CQ (ng/ml) 19.68 ±ND 
 
ND = Not determined 
Mobile phase = Toluene: Ethyl acetate: Acetic acid (16:4:1)  
IC50-values are given as a mean value with ± standard deviations of 2 independent experiments 
 
Fractionation showed an enhancement in activity of the whole leaf extract (Table 25). 
TLC band 2 of the gel extract was the most active gel fraction. Interestingly, the 
inactive outer leaf extract revealed several active fractions when separated. TLC 














was investigated further due to the promising results obtained during fractionation as 
well as sufficient amounts as the gel largely consists of water. TLC separation 
resulted in low yields, thus column chromatography (CC) was investigated, as an 
alternative method, as described in Chapter 7 (7.4.1). The outer leaf DCM extract was 
fractionated using CC (Table 26). Fractions were analyzed by TLC and those with 
similar profiles were combined.  
 
Table 26 Fractions collected via column chromatography 
 
Fractions Mobile phase 
  Ethyl acetate:Petroleum ether 
1 – 48  7:3 
49 – 55  4:6 
 
The purity of combined fractions was analyzed via HPLC. Two peaks detected at 




























Figure 44 HPLC profile of compound 3 on a C18 RP column (λ = 250 nm)  
HPLC conditions: Mobile phase H2O:ACN using a gradient of 10 – 100% ACN (20 
























Compound 3 was obtained by combining CC-fractions 17 – 19, 25 – 27 and 28 – 29 
which revealed a major peak at a retention time of 12.1 min (Fig 44). The HPLC 
profile of compound 3 contains several smaller peaks which is characteristic of 











Figure 45 HPLC profile of AE on a C18 RP column (λ = 250 nm)  
HPLC conditions: Mobile phase H2O:ACN using a gradient of 10 – 100% ACN (20 
min), 100% ACN hold (2 min), 100 – 10% ACN (3 min), 10% ACN hold  (5 min).  
 
Aloe-emodin (Sigma) is commercially available and was used for bioactivity testing 
and comparative purposes during the analytical investigation of compound 3. 
Compound 3 showed similarities in the UV spectra and retention time to the known 
compound aloe-emodin (AE) (Fig 45). LC-MS analysis showed that the molecular ion 
of AE (m/z 269) is present in compound 3 (Figures 46 and 47). AE is a degradation 
product of aloin thus its presence in A. ferox is expected (Saccù et al., 2001). The MS 




































 -Q1: 0.211 min from Sample 1 (TuneSampleID) of MT20080702122144.wiff (Turbo Spray) Max. 4.1e5 cps.
















































Figure 46 LC-MS spectrum of AE  
LC-MS conditions: Negative ionization in MP ACN:0.1% formic acid (1:1), infused 5 
µl. 
 
 -Q1: 0.110 min from Sample 1 (TuneSampleID) of MT20080702124915.wiff (Turbo Spray) Max. 3.2e5 cps.





































248.966.1 131.2103.0 240.7140.9 180.789.2




Figure 47 LC-MS spectrum of compound 3  




















Compound 4 was obtained by combining CC-fractions 51 – 55.  HPLC was used to 
determine the purity of compound 4. The UV spectrum of this compound was 
compared to published data. The spectral data of compound 4 was identical to two 
known compounds namely aloesin and aloeresin (Zonta et al., 1995). The absorbance 
of aloesin at 250 nm is stronger than the absorbance at 300 nm; while the opposite 
applies to aloeresin. The UV-spectrum obtained for compound 4 revealed that the 
absorbance at the 251 nm band is higher than the 289.9 nm band, which compares 












Figure 48 HPLC profile of compound 4 on a C18 RP column (λ = 280 nm) 
HPLC conditions: Mobile phase H2O:ACN using a gradient of 10 – 100% ACN (20 








































Aloesin is a C-glycosylchromone with a molecular formula of C19H22O9 (Fig 49) 
(Haynes et al., 1970). Aloesin has a molecular ion of m/z 394 which was used for 
identification via LC-MS analysis. The molecular ion (m/z 394) was present in 
compound 4 but relatively high background signals showed that the compound 
contains impurities (Fig 50). The LC/MS data did provide further evidence that the 
compound is not aloeresin. No standard was available for comparative testing. LC-
MS/MS analysis of m/z 394 revealed product ions m/z 324.8, 230 – 240, ±200, ±170, 
62.2 and 34.8 (Fig 51). Previous studies showed similar product ions for aloesin 
(Dell’Agli et al., 2007). The fragmentation pattern confirmed that compound 4 is 
aloesin. 
 
 -Q1: 0.345 min from Sample 1 (TuneSampleID) of MT20080702131402.wiff (Turbo Spray) Max. 2.6e5 cps.













































131.0 285.0 309.4 337.2
160.7 445.3387.2181.079.8 198.9 353.2209.0 473.0
225.2 403.1248.9 409.3297.0 381.1137.2 333.2101.1
339.9303.8266.8215.2170.8 425.8 441.0 468.6106.2 490.9
 
Figure 50 LC-MS spectrum of compound 4. 
 
 -MS2 (393.15) CE (-51): 26 MCA scans from Sample 1 (TuneSampleName) of P2_InitProduct_Neg.wiff (Turbo Spray) Max. 4000.0 cps.
































Figure 51 LC-MS/MS spectrum of m/z 394  
















5.3 In vitro bioactivity of compounds 1 – 4  
 
The test compounds were screened for in vitro antiplasmodial activity against the 
CQS D10 strain of P. falciparum as described in Chapter 7 (7.6). Cytotoxicity 
screening was done using the CHO cell-line and antimycobacterial testing was done 
against M. aurum A+ according to methods in 7.7 and 7.9 respectively. IC50-values are 
given as a mean value with standard deviations of 2 independent experiments. 
 
Table 27 IC50-values of compounds against the CQS D10 strain of P. falciparum and 
cytotoxicity of compounds (±SD) 
 
Sample Antiplasmodial Cytotoxicity SI
a
 
 D10: IC50 (µg/ml) CHO: IC50 (µg/ml)  
Compound 1 2.92 ±0.01 50.58 ±5.94 17.32 
Compound 2 49.09b _ _ 
Compound 3 > 100b _ _ 
Compound 4 12.51b > 100 ND 
Aloe-emodin > 100 _ _ 
Chloroquine 16.26 ±2.42 _ _ 
Emetine _ 0.06 ±0.0 _ 
 
Selectivity index (SIa) = cytotoxicity IC50/antiplasmodial D10 IC50  
b = tested on one occasion in duplicate 
ND = not determined 
 
Compound 1 showed moderate activity with an IC50-value of 2.9 µg/ml (Table 27). 
Cytotoxicity results revealed a SI of 17 which indicates that the potency of the 
compound is selective for the malaria parasite. Compound 2 did not show activity 
(IC50 = 49.09 µg/ml). Compound 3 and AE were not active against the CQS D10 
strain of P. falciparum with IC50-values higher than 100 µg/ml. Compound 4 was 
slightly active against the CQS strain of the parasite with an IC50-value of 12.5 µg/ml. 
AE has been reported to have moderate antibacterial activity against Micrococcus 
kristinae, B. cereus, B. subtilis, S. aureus, S. epidermis, E. coli and Shigella sonnei 
(Kambizi et al., 2004 and Coopoosamy et al., 2006). This is the first time to our 









































Figure 52 Dose-response curve of Aloe-emodin against M. aurum A+  
 
A MIC of 31.25 µg/ml was determined based on visual growth of M. aurum A+. The 
compound was further tested to establish an IC50-value. AE showed moderate activity 
against M. aurum A+ with an IC50-value of 28.9 µg/ml (Fig 52).  
 
5.4 In vivo antiplasmodial activity 
 
The DCM extract of the whole leaf was investigated for in vivo antiplasmodial 
activity according to 7.10 of Chapter 7. The CQS P. berghei ANKA and CQR P. 
yeolii NS strains were used in a four-day suppressive test. Plant extract was prepared 
to 400 mg/kg bw in 8% ethanol diluted with 5% sodium bicarbonate and orally 
administered. Three groups of four mice each were tested against the CQS strain and 
three groups consisting of three mice were tested against the CQR strain. Averaged 
parasitemia were compared to the untreated control group to assess activity. The 
crude extract did not show suppression of parasitemia on day 4 against the CQS P. 
berghei strain (Fig 53). A suppression of parasitemia was observed against the CQR 
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Figure 53 A. ferox: Average percentage parasitemia using 4-day suppressive test 
against the CQS P. berghei ANKA strain and CQR P. yeolii NS strain  
 
Table 28 Percentage growth inhibition of A. ferox against the P. yeolii NS strain 
Days post-infection A. ferox (DCM) CQ control 
   
4 55.91 % 68.82 % 
7 22.90 % 80.41 % 
 
Inhibition of parasitemia of 55.9% was observed after 4 days of treatment against the 
CQR P. yeolii NS (Table 28). The parasitemia against the CQR strain increased 
steadily after termination of treatment on day 4. No toxic effects were observed for 
















5.5.1 In vitro bioactivity 
 
The winter collections of A. ferox were four times more active against the CQS strain 
of P. falciparum than the summer collections. Temperature and rainfall play an 
important role in the development and metabolism of plants (Trease and Evans et al., 
1996). A higher percentage aloin, the major compound in the dried leaf juice, was 
observed during summer than winter months (Trease and Evans et al., 1978). Previous 
studies showed that aloin is inactive against the malaria parasite (van Zyl et al., 2002). 
The decrease in aloin-type constituents during winter months might account for the 
increased antiplasmodial activity. The inner gel contains several compounds which 
are believed to be biologically active (van Wyk et al., 1996 and Loots et al., 2007). 
Therefore the leaves collected in winter were separated into the gel and outer leaf. 
The whole leaf extractions were more active against P. falciparum than the gel and 
outer leaf separated. Various studies have focused on the bioactivity of the inner gel 
of Aloe species as opposed to the whole leaf. 
 
An enhancement in activity was observed with fractionation. Bioassay-guided 
fractionation of the whole leaf extract yielded two compounds. Compound 1 was the 
most active against the CQS strain of P. falciparum with an IC50-value of 2.9 µg/ml. 
The chemical structure of compound 1 was not determined due to insufficient 
material. LC-MS analysis suggested a mass ion of m/z 404 for compound 1. 
Compound 2 was inactive with an IC50-value of 49.1 µg/ml. The HPLC evaluation of 
compound 2 showed that it degraded in solution thus no structure determination was 
done. The absorbance data suggests compound 2 has a chromone-like structure (Zonta 
et al., 1995).  TLC separation of the gel and outer leaf extracts enhanced 
antiplasmodial activity. The activity of the outer leaf extracts ranged from an IC50 = 
80 – 100 µg/ml but the fractions showed increased activity ranging from IC50 = 2 – 9 
µg/ml. This trend in activity led to further investigation of the outer leaf extract which 
yielded two major compounds (3 and 4). The HPLC profiles of compound 3 and AE 
were identical. The identity of compound 3 as AE was further confirmed via LC-MS 














antiplasmodial activity. AE was moderately active against M. aurum. HPLC and LC-
MS analyses assigned compound 4 as the known compound aloesin. Compound 4 was 
slightly active against the CQS strain of the parasite and showed no cytotoxicity. 
Metabolite studies of aloesin showed that the C-glycosyl bond is cleaved by human 
intestinal bacteria (Che et al., 1991). Aloesin (m/z 394) is converted to two 
metabolites aloesone (m/z 232) and aloesol (m/z 234). LC-MS/MS analysis of 
compound 3 (m/z 394) showed product ions similar to published data (Dell’Agli et 
al., 2007). Degradation of aloe constituents is a common phenomenon during 
phytochemical investigations (Zonta et al., 1995). It is possible that compounds 1 and 
2 might be degradation products or derivatives of known compounds.  
 
5.5.2 In vivo activity 
 
In vivo activity is influenced by pharmacodynamic and pharmacokinetic properties 
which might enhance or reduce activity (Kirby et al., 1996). In vitro screening in 
combination with an in vivo evaluation is essential in determining the bioactivity 
profile of a plant extract. Several examples exist of compounds and plants which 
exhibit in vitro activity but lack in vivo activity and vice versa (Phillipson et al., 
1993). Therefore the crude extract of A. ferox was investigated for in vivo 
antiplasmodial activity. The crude extract was more active in vivo against the CQR 
strain than the CQS strain of the parasite. The crude extract inhibited parasitemia by 
more than 50% on day 4 of treatment against the CQR strain of Plasmodium. 
Interestingly the crude extract was less active in vitro against the CQR strain than the 
CQS strain of P. falciparum. The crude extract did not show in vivo toxicity at the 

















































6.1 Siphonochilus aethiopicus 
 
6.1.1 In vitro bioactivity 
 
The traditional use of S. aethiopicus (wild ginger) for the treatment of malaria and 
malaria-like symptoms initiated this scientific investigation. The in vitro 
antiplasmodial investigation of the EA extract revealed activity against P. falciparum. 
Bioassay-guided fractionation resulted in the isolation of three structurally-related 
furanoterpenoids. Chemical analogues of natural products are often obtained from the 
original plant as many compounds exist as groups of structurally-related metabolites 
within a species or related species and genera of one or more families (Kirby et al., 
1996). These naturally occurring metabolites can provide structure activity 
relationships which might explain the source of activity. This class of compounds has 
been isolated from the Zingiberaceae family (Hikino et al., 1968).  A 
furanosesquiterpenoid, furanodiene, was isolated from Curcuma zedoaria 
(Zingiberaceae). Similar furanosesquiterpenoids have been previously isolated from 
marine sources (Yamakawa et al., 1975; Mollo et al., 2005 and Iguchi et al., 1986). In 
a recent publication by Pink et al., (2005) the criteria for selecting a hit compound 
was specified as follows:  
• In vitro activity with an IC50-value ≤ 1 µg/ml  
• Selectivity index ≥ 10 fold 
 
According to these criteria the compounds isolated did not show significant in vitro 
antiplasmodial activity for them to be considered as hit compounds. However the 
selectivity of the compounds towards the CQR K1 strain compared to the CQS D10 
strain of P. falciparum is noteworthy. The observed selectivity towards the CQR 
strain indicates that these compounds act by a mechanism unrelated to CQ. The 
reason for this activity is not known. The activity of the EA extract of S. aethiopicus 
and compound 3 is comparable against both strains of P. falciparum. Compound 3 
and the EA extract showed a two-fold increase in activity towards the CQR K1 strain 














CQR K1 strain compared to compound 1. Interestingly, the only difference in the 
structure of compound 1 and 2 is the substitution of the OH-group with hydrogen 
which results in a three-fold increase in activity against the CQR K1 strain. 
Introduction of an additional double bond in ring C (compound 3) further improves 
activity against both strains. It is possible that the antiplasmodial activity of these 
compounds can be attributed to the furan moiety in the structure. Recently, two 
privileged substructures, a 2(5H)-furanone and a dihydrofuran-4-one moiety were 
identified as the possible chemical entities responsible for antiplasmodial activity of 
hirsutinolides isolated from Vernonia staehelinoides (Pillay et al., 2007). The 
mechanism of action of this class of antiplasmodial compounds is not known. The in 
vitro antiplasmodial data suggests that the activity of the crude plant extract is due to 
compound 3. Compounds 2 and 3 are more active against the chloroquine resistant 
strain of P. falciparum than the chloroquine sensitive strain. The structure-related 
increase in antiplasmodial activity against the CQR strain suggests that the basic 
structure of these compounds may be useful as a scaffold for further synthesis of 
derivatives. However the SPE fractions were more active than the compounds 
isolated, indicating that the activity of the crude extract might be due to the 
synergistic effect of different components. This study provides evidence of 
antiplasmodial compounds present in this plant which may play a role in the 
traditional use of S. aethiopicus in he treatment of malaria.  
 
Previous studies on a crude extract of this plant showed antibacterial activity against 
S.  aureus and K. pneumoniae (Stafford et al., 2005). Broad spectrum activity against 
a range of miroorganisms is essential to fully evaluate the potential of novel 
compounds and traditional remedies. The semi-pure fraction consisting of all three 
compounds was extracted using a pH 11 buffer. This fraction was tested against M. 
aurum which serves as a preliminary antimycobacterial test for M. tuberculosis. The 
fraction was found to be moderately active. No activity was found with the isolated 
compounds against M. tuberculosis, S. aureus, K. pneumoniae and C. albicans. The 
process of bioassay-guided fractionation might reveal more active compounds as it 
















6.1.2 In vivo schizontocidal activity 
 
In vivo activity is influenced by pharmacokinetic and pharmacodynamic properties of 
the drug. The promising in vitro activity of the EA extract and compound 3 are 
selective to the malaria parasite particularly the CQR strain of P. falciparum. The SPE 
fractions showed greater in vitro activity than the three isolated compounds which 
suggested that the antiplasmodial activity might be due to synergism rather than a 
single compound. All in vivo experiments were performed against the CQR P. yeolli 
NS strain due to the observed in vitro selectivity towards the CQR strain. The in vivo 
schizontocidal activity of the EA extract and compound 3 were evaluated in a 4-D 
suppressive test. HPLC analysis showed that compound 3 is one of three major 
compounds in the EA extract. The EA extract suppressed parasitemia during 
treatment but not after the termination of treatment. Compound 3 also showed a 
suppression of parasitemia on day 4. The EA extract was administered 4-fold higher 
dose than compound 3. However the EA extract inhibited parasite growth more than 
compound 3 at the administered dosages. These results supported the hypothesis that 
more than one compound can be responsible for the antiplasmodial activity of the S. 
aethiopicus. An in vivo study to compare the schizontocidal activity of the EA extract 
and isolated compounds at the same dose will be helpful to draw further conclusions.  
 
The schizontocidal activity of the EA extract during the 4-D treatment was further 
investigated using a 7-D suppressive test. Drug formulations can have an effect on 
bioavailability and pharmacokinetics resulting in either increased or decreased in vivo 
schizontocidal activity (Peters et al., 2002). In the 7-D test the activity of the EA 
extract in two formulations, an aqueous-based 5% SB (with addition of 5% ethanol) 
and lipid-based SMEDDS formulation, were compared at the same dose. Suppression 
of parasitemia on days 4 and 7 was observed with the 5% SB formulation. The 
SMEDDS formulation did not show any suppression of parasitemia in the 7-D test. 
Interestingly the parasitemia remained unchanged from day 5 to 7 with the SMEDDS 
formulation. No parasite clearance was observed with the EA extract in a curative 
experiment. In a prophylactic study of S. aethiopicus (EA) a weak to moderate effect 
was observed. The dose formulation of the EA extract had an effect on its in vivo 














treated for four or seven days. This study gives support to the traditional use of wild 
ginger for the treatment of malaria.  
 
Lipophilic quassinoids isolated from B. javanica have promising antiplasmodial 
activity but were also very toxic (O’Neil et al., 1987). This medicinal plant like A. 
annua has been used as a traditional medicine for centuries in an aqueous decoction. 
Aqueous decoctions can contain lower amounts of active constituents and the reduced 
concentration can lead to less toxicity (Kirby et al., 1996). The route of administration 
and traditional preparation of traditional medicine plays an important role in 
tolerability and efficacy. Wild ginger is traditionally used as an infusion or the fresh 
rhizomes and roots are chewed. This part of the study focussed on isolating novel 
antiplasmodial compounds thus a selective approach was used in evaluating the plant 
material. Scientific investigations using the traditional formulations might reveal 
better activities as more compounds might be available.  
 
6.1.3 In vivo bioavailability and metabolism  
 
LC-MS/MS technology has revolutionized bioanalytical analyses and has become the 
method of choice for evaluation of pharmacokinetic studies. Advances in 
bioanalytical methods over the past decade have paved the way forward for 
techniques that are higher in throughput and sensitivity (Shah et al., 2000). The 
criteria for method validation recommended by the Food and Drug Association 
Guidance for accuracy, precision, selectivity, sensitivity, reproducibility and stability 
serves as a guideline for bioanalytical method development of small molecules 
(Bansal et al., 2007). These parameters were taken into account during method 
development. A novel method to evaluate in vivo pharmacokinetic factors such as 
absorption and metabolism was developed using a mouse-model. The use of small 
animals for pharmacokinetic studies is ideal for plant-derived compounds as these 
studies are often neglected due to insufficient quantities. LC-MS/MS analyses were 
performed using only 10 µl of plasma. The small sample size needed for analysis 
eliminated the sacrifice of animals at time points. Thus a small number of animals 















The absorption and metabolism of a compound can influence its in vivo activity and 
toxicity. If a drug is poorly absorbed it may not be available or may be available in 
low concentrations at the target site. Hence a compound which is active in vitro but 
not active in vivo such as compound 3 might be as a result of poor absorption. 
Metabolism within an in vivo system involves a variety of enzymatic pathways and 
the production of numerous novel compounds at varying concentrations. These newly 
formed metabolites can increase or decrease the activity of a compound. The 
pharmacokinetic study was designed two-fold, the first study investigated the 
bioavailability of compound 3 and the second study investigated the metabolism of 
compound 3.  
 
The in vivo bioavailability of compound 3 was investigated using an aqueous- and 
lipid-based SMEDDS formulation. The formulations were compared using oral and 
SC routes of administration. The bioavailability study of compound 3 revealed that 
the SMEDDS formulation administered either orally or subcutaneously, is better 
absorbed than the DMSO formulation. The SC route of administration resulted in 
higher plasma levels. A delayed trend in absorption was observed with the SC 
administration of compound 3 in the SMEDDS formulation.  
 
The bioavailability of the EA extract was investigated to determine if administering 
the mixture would result in better absorption of compound 3. The EA was orally 
administered at a low dose of 400 mg/kg bw and a high dose of 800 mg/kg bw in 
SMEDDS formulation. Compound 1 is the most abundant constituent in the EA 
extract and was absorbed in greater quantities than compounds 2 and 3. The 
SMEDDS formulation facilitates a delayed effect on absorption of compound 3 given 
either alone or in the EA extract. The slower release of compounds was not evaluated 
as no blood samples were taken beyond 5 hrs. The disadvantage of a small animal 
study design is limitation of blood sampling intervals. The plasma levels of compound 
3 in the EA extract was higher than that of the pure compound. The EA extract was 
more active in vivo than compound 3 against the CQR P. yeolli strain. Improved 
absorption of compound 3 was observed with the EA extract which might explain the 
increased in vivo activity of the extract. The bioavailability data suggests that 














plasma levels of compound 3 are three times less than the concentration needed to 
inhibit 50% of parasite growth and this could account for its weak in vivo activity.  
 
The lack of in vivo activity of compound 3 can also be explained by rapid metabolism 
and the subsequent formation of inactive metabolites. Metabolism plays an important 
role in drug availability and thus efficacy. A preliminary metabolism study was 
performed by oral administration to access the effect of phase I metabolism on 
compound 3.  CYP is a superfamily of enzymes responsible for phase I hepatic 
metabolism and the most important subfamilies in the human genome are CYP 1A, 
CYP 2C, CYP 2D and CYP 3A (Granvil et al., 2003, Willcox et al., 2004 and Dresser 
et al., 2000). Recent studies reported that the CYP enzyme system plays an important 
role in the biosynthesis of β-substituted furan moiety in furanoterpenes (Gaikwad et 
al., 2002). Therefore it is likely that this class of compounds can undergo enzymatic 
metabolism by CYP enzymes. Compound 3 was not detected in the matrixes (blood, 
urine and faeces) evaluated for the metabolism study. A more intense investigation 
might reveal metabolites as this metabolite study had time and sample constraints. 
The precursor experiment was conducted to evaluate the presence of the major 
product ion.  The expected fragmentation was not observed with this experiment. Poor 
oral bioavailability is generally associated with substrates that have a high phase I 
elimination. The metabolite study further provided evidence that compound 3 
probably undergo phase I metabolism. The compound might be metabolized by novel 
pathways thus the predicted metabolites could not be detected. No neutral loss 
experiments to search for expected metabolites were performed due to the lack of 
visible metabolites during the precursor experiment. Further fine-tuning of the LC-
MS method and more advanced technologies such as specialised software packages in 
metabolite identification may reveal better results. This study could not detect visible 
metabolites of compound 3 but provides a platform for future work.  
 
Different compounds in a crude extract can act as an inhibitor of metabolic enzymes 
resulting in higher plasma concentrations. This phenomenon can shed light on the 
increased absorption of compound 3 from the EA extract. The pharmacokinetic 
investigation suggested that the weak in vivo activity of compound 3 is due to poor 


















6.2 Aloe ferox 
 
Environmental conditions play an important role in the development and metabolism 
of plants (Trease and Evans et al., 1996). The effect of continuous rain can lead to 
leaching of water-soluble components from the leaves and roots. This phenomenon 
has been observed with alkaloid-, glycoside- and volatile oil-producing plants and 
could explain a decrease of active constituents in winter. However the opposite was 
observed in this study. The most potent extraction solvent was DCM which extracts 
non-polar constituents while the water extract showed no antiplasmodial activity. This 
indicates that the active components of the plant are non-polar. Lesser activity in 
summer collections can be accounted for by the effect of dry and stressed summer 
conditions which might yield fewer amounts of the active constituents. Studies on A. 
vera have shown that the barbaloin content and distribution in leaf parts may play a 
role in the plant’s defence mechanism against herbivores (Esteban-Carrasco et al., 
2001). In this study higher amounts of aloin-type compounds were observed in the 
summer collections. The results support the general rule supporting the collection 
leaves during the flowering season. Chemical similarities were observed with plant 
extracts from two different locations which corresponded with previous studies by 
Viljoen (2001).  
 
Two unknown compounds were isolated from whole leaf DCM extracts. Compound 1 
was the most active compound against the CQS strain of P. falciparum and showed 
little cytotoxicity. The molecular ion of compound 1 (m/z 404) was determined. The 
structure elucidation of compound 1 was not determined due to insufficient material. 
Compound 2 was inactive against the CQS strain of P. falciparum. HPLC data 
showed that compound 2 has a chromone-like structure.  Two known compounds, 
aloe-emodin and aloesin, were isolated from the outer leaf extract. Aloin is a known 
pro-drug for AE thus the presence of aloin in the DCM extract can account for the 














HPLC and LC-MS analyses. AE did not show antiplasmodial activity and was 
moderately active against M. aurum. Aloesin was slightly active against the CQS 
strain of the parasite and showed no cytotoxicity. Compounds 1 and 2 might be 
degradation products or derivatives of known compounds as degradation products 
often occur in aloes (Zonta et al., 1995). Fractionation of the DCM extracts showed an 
enhancement in activity in vitro but only one of the four compounds isolated was 
active. There might be other compounds present in the crude extract which 
contributes to the antiplasmodial activity or the activity might be caused by a 
collective approach of different components instead of one compound. Aloe gel 
components have been shown to work synergistically to address inflammation and 
wound healing (Lindsey et al., 2002).  
 
In vivo screens are an imperative part of bioactivity testing as it might lead to the 
enhancement or reduction in activity (Kirby et al., 1996). Studies showed that berberis 
alkaloids have weak in vitro activity against E. histolytica but have significant in vivo 
activity (Subbaiah et al., 1967 and Kirby et al., 1996). The whole leaf DCM extract 
was further investigated for in vivo schizontocidal activity. The DCM extract 
suppressed parasitemia on day 4 of treatment against the CQR strain but had no effect 
on day 4 against the CQS strain of Plasmodium. Thus the DCM extract revealed 
greater suppression of parasitemia against the CQR strain than the CQS strain of the 
parasite. These results did not correspond with the in vitro activity of the crude extract 
which was more active against CQS strain of the parasite. Studies have shown that in 
vitro and in vivo activity does not always correlate (Phillipson et al., 1993). No 
toxicity was observed for the crude extracts with in vitro or in vivo testing. It is 
evident by the wide range of traditional use of Aloes that its effect may not be 

























The furanoterpenoid skeleton of the compounds isolated from S. aethiopicus can be 
used as a scaffold for further chemical modifications. The synthesis of tricyclic 
furanoterpenoids and the possible biosynthetic route for the formation of the furan 
skeleton in lower furanoterpenoids has been investigated (Moiseenkov et al., 1997 
and Gaikwad et al., 2002). The synthesis of the furanoterpenoid skeleton and 
derivatives might be possible through a synthetic and biosynthetic route. The 
synthesis of derivatives will be to produce antiplasmodial compounds with enhanced 
in vitro and in vivo activity and low cytotoxicity. The bioavailability of active 
derivatives can be tested in vivo using the methods developed in this study. The 
separation methods developed for S. aethiopicus will be useful to further isolate 
compounds from this plant. Additional in vitro experiments to evaluate the effect of 
the isolated compounds as well as the EA extract in combination with CQ on CQR 
strains of P. falciparum can be conducted. In vivo schizontocidal activity of the crude 
extract and antiplasmodial compounds can be further investigated.  The bioactivity 
testing of novel compounds against a wide variety of organisms should be encouraged 
to effectively evaluate potential hit compounds. A comparative study to evaluate oral 
and intravenous administration might help to understand if it undergoes phase I or 
phase II metabolism.  
 
 
6.4 Research outputs 
 
 
• Oral presentation of part of thesis: South African Pharmacology & Toxicology 
Congress, 2007.  
• Oral and poster presentation of part of thesis at the Young Scientist Workshop: 
7th Joint Meeting of AFERP, ASP, GA, PSE and SIF, 2008. 
• The bioactivity activity of novel furanoterpenoids isolated from Siphonochilus 
aethiopicus. Authors: Carmen Lategan, William Campbell, Tracy Seaman and 










































7. Materials and Methods 
 
7.1 Plant collection 
 
A. ferox was collected at Kirstenbosch botanical gardens and Buffelsfontein farm, 
Albertinia in the Western Cape (South Africa). Collection was done in summer and 
winter. Chris Cupido, a botanist at the Kirstenbosch Research Centre (Cape Town) 
verified the collected plant material. A voucher specimen (Lategan 1) was submitted 
to the Compton herbarium at Kirstenbosch national botanical gardens (Cape Town). 
S. aethiopicus was initially donated by Nigel Gericke (South African National 
Biodiversity Institute, Durban). Plant material was subsequently supplied by the New 
Guelderland sugar estates in Kwazulu-Natal, South Africa (batch number 200/ngse 
02) and was collected in October 2002. The rhizomes were received in a freeze dried 
form and ground to a fine powder. A voucher specimen (barcode number 3667) was 
submitted to the Bolus herbarium at the University of Cape Town. Plant material was 
stored at room temperature until extraction. 
 
7.2 Extraction of plant material 
 
The preparations of extracts were not done according to the traditional use. The 
drying process of plants results in the rupture and degradation of cell membranes 
which can lead to the extraction of more compounds (Stafford et al., 2005). Plant 
material was extracted using various solvents, filtered and the filtrate reduced under 
pressure using a Büchi rotavapor R-205 (Büchi Labortechnik AG Schweiz). 
Extraction solvents were selected based on previous studies (Clarkson et al., 2004 and 
Toyer et al., 2005). A. ferox leaves, leaf exudate and cold H2O extractions were 
freeze-dried using a DURA-DRV II instrument (FTS SYSTEMS, NY USA). The 


















7.3 Fractionation and purification of compounds from S. aethiopicus  
 
7.3.1 Solid Phase Extraction 
 
SPE was done on a 70 ml reverse phase C18 Isolute column cartridge (2.6 x 13.0 cm, 
10 g sorbent, IST Ltd, Anatech, South Africa). The extract was dissolved in ACN and 
water and loaded onto the column. A previous study showed that the 60% ACN and 
80% ACN fractions were the most active (Toyer et al., 2005). The extract was eluted 
with a gradient of decreasing polarity (ACN:H2O) with 10% increments of ACN 
starting from 50:50 (ACN:H2O) to 100:0 (ACN:H2O). A vacuum was applied to the 
cartridge and the fractions collected were concentrated under reduced pressure 
followed by freeze drying to displace water. This procedure was repeated several 
times to obtain sufficient material for further fractionation. 
 
7.3.2 Liquid-liquid extraction 
 
This procedure was done to scale-up the fractionation process of the crude extract of 
S. aethiopicus. Britton Robinson universal buffers (pH 2 – 12) were prepared with 
solvent A (6.005 g/L acetic acid, 11.53 g/L phosphoric acid and 6.183 g/L boric acid) 
and solvent B (0.5 M NaOH).  
 
Method development: A 10 mg/ml stock solution of the crude extract was prepared in 
EA. 100 µl of the stock solution was added to 1 ml of the respective pH buffer and 5 
ml EA. This mixture was vortexed, centrifuged at 13 000 rcf for 5 min and the 
supernatant removed. The organic solvent was removed using a cold trap system 
(Jouan RC 10.10). The dried material was reconstituted in methanol or DMSO and 
evaluated using HPLC. 
 
Optimisation of extraction: A stock solution of ±60 mg/ml of the crude extract in EA 
was prepared. Then 10 ml of the stock solution was added to 50 ml pH 11 buffer and 
250 ml EA (5 x volume of pH buffer). The mixture was shaken for 15 min and the 
















7.3.3 High Performance Liquid Chromatography  
 
HPLC was done using a Waters 1525 system consisting of a binary HPLC pump, a 
photodiode array detector, a fraction collector and an auto sampler controlled by 
Millennium v.4.0 software. Alternatively, a Shimadzu LC10AS high pressure system 
consisting of binary LC10AS pumps, a diode array detector and an auto sampler 
controlled by Shimadzu software was used. All solvents were of analytical grade 
(Sigma-Aldrich, South Africa) and Millipore water (Milli-Q water system) was used.  
 
7.3.3.1 Analytical HPLC 
 
The UV absorption was detected with a photodiode array detector. Analytical HPLC 
profiles were obtained using a Supelco Discovery RP C18 (15 cm x 4.6 mm, 5 µm) 
column with a C18 guard column (5 µm). The flow rate was set at 1 ml/min and 50 µl 
of a 1 mg/ml sample concentration in methanol, ACN or DMSO was injected onto the 
column. The mobile phase H2O:ACN was run at a gradient of 10% ACN to 100% 
ACN in 20 min with a hold at 100% ACN for 2 min, then reduced to 10% ACN in 3 
min and kept at 20% for 5 min. The gradient was set according to this method unless 
stated otherwise. 
 
7.3.3.2 Semi-preparative HPLC 
 
HPLC collections were performed on a semi-preparative Supelco Discovery C18 (25 
cm x 10 mm, 5 µm) column attached to a C18 guard column (5 µm) with the flow rate 
adjusted to 2 ml/min.  The diode array detector was set to UV absorption at λ = 254 
nm as all three peaks were clearly detected using this wavelength. The mobile phase 
was adjusted to a gradient of 40% ACN to 100% ACN in 20 min with a 2 min hold at 
100% ACN, then reduced to 40% ACN in 3 min and conditioned at 40% for 5 min 
before the next run. Samples of 10 mg/ml were prepared and 50 µl was injected onto 
the column during method development. Further optimisation for large scale 

















7.3.4 Analytical methods for structure elucidation 
 
The NMR spectra were performed on a Varian Unity Inova 600 MHz and accurate 
mass determination was recorded on a Waters API Q-TOF Ultima system (University 
of Stellenbosch, Stellenbosch). Optical rotations were done on a Perkin-Elmer 241 
polarimeter at 589 nm (Na D-line) using a 1,001 dm cell (CSIR, Pretoria). The 
compounds were dissolved in methanol at a concentration of 10 mg/ml. The melting 
point was measured on a SANYO Gallenkamp variable electrical apparatus (United 
Scientific, Cape Town) and a Reichert-Jung Thermovar hot stage microscope 
(Department of Chemistry, University of Cape Town).   
 
7.4 Fractionation and purification of compounds from A. ferox  
 
SPE was performed as described above with an adjustment of 20% increments of 
ACN starting from 20:80 (ACN:H2O) to 100:0 (ACN:H2O). Additional separation 
using SPE was done with 5% increments of A N starting from 40:60 (ACN:H2O) to 
100:0 (ACN:H2O). Purity of fractions and compounds was evaluated via HPLC and 
TLC. HPLC conditions were the same as for S. aethiopicus analysis or adjusted to a 
gradient of 20% ACN to 100% ACN in 30 min with a hold at 100% ACN for 5 min, 
then reduced to 20% ACN in 5 min and kept at 20% for 2 min (7.3.3.1). 
 
7.4.1 Column chromatography 
 
The outer leaf extract of A. ferox (DCM) was separated using column chromatography 
(silica gel type H, Sigma). Approximately 2g of the crude extract dissolved in DCM 
was loaded onto the column. The extract was washed with 100% petroleum ether (PE) 


















7.4.2 Chromatotron and thin layer chromatography 
 
SPE fractions of A. ferox (DCM) whole leaf extract were further separated using a 
chromatotron (Harrison, Model 8924). The chromatotron is a preparative separation 
technique which is centrifugally accelerated. The sample was loaded onto a circular 
chromatotron plate which rotated under UV-light. Separation was performed on 1 mm 
plates (Silica gel PF254 containing gypsum, Merck). Solvent systems of varying 
polarities were used to elute bands. The solvents form concentric bands which are 
collected together with solvent from the edge of the rotating plate. This method 
bypasses the time consuming step in TLC of scrapping-off bands, washing silica gel 
and filtering. 
 
Chromatotron fractions of A. ferox were further fractionated using PTLC and 
analytical TLC techniques with toluene:ethyl acetate (93:7) as the MP. SPE fractions 
were also separated using TLC in MP developed by Duncan (2001).  
 
7.4.3 Analytical methods for structure elucidation 
 
Analytical methods using HPLC were used to determine the UV-absorption of 
compounds (7.3.3). An Applied Biosystems API-2000 mass spectrometer (MS) was 
used to determine the molecular ion of the compounds. Compounds were infused at 1 
µg/ml in the both negative and positive ESI modes to select the molecular ion of 
interest. The best results were achieved in the negative ion mode infused in an acidic 
chemical environment (0.1% formic acid: ACN, 1:1, v/v) at a flow rate of 5 µl/min. 
 
7.5 Preparation of samples for antiplasmodial and cytotoxicity assay 
 
Chloroquine diphosphate (Sigma) was used as the reference drug for antiplasmodial 
assays. Emetine dihydrochloride (Sigma) was the reference drug for cytotoxicity 
assays. Stock solutions for test samples were prepared to 2 mg/ml. Test samples were 
dissolved in MeOH:H2O (1:9) or DMSO:H2O (1:9). A solvent control was carried out 














exposed did not have an effect. The highest concentration of methanol (0.5%) to 
which the parasites or cells were exposed had no measurable effect on parasite 
survival 
 
7.6 In vitro antiplasmodial testing 
 
7.6.1 Preparation of medium for culturing malaria parasites 
 
Parasites were maintained in medium containing 10.4 g/L RPMI 1640 with glutamine 
but without NaHCO3 (BioWhittaker) supplemented with Albumax II (GibcoBRL) (5 
g/L), 4 g/L glucose, 6 g/L Hepes (N-[2-hydroxyethyl]-piperazine-N1-[2-
ethansulphonic acid]) (Sigma-Aldrich), 0.088 g/L Hypoxanthine, and 1.2 ml/L (0.05 
g/L) gentamycin (Sigma-Aldrich). The RPMI contains a colour indicator, which 
appears orange at the desired pH. Culture medium or reagents were filtered under 
pressure firstly through a pre-filter (0.45 µm) to remove impurities followed by filter 
sterilization through a 0.22 µm filter. 5% sodium bicarbonate (8.4 ml) was added to 
200 ml medium which was then referred to as complete medium. Wash medium was 
prepared and filtered the same as culture medium but did not contain albumax. The 
same amount of sodium bicarbonate solution was added to wash medium. D-sorbitol 
(5%) solution was filter sterilized. Medium and reagents were stored at 4°C.  
 
7.6.2 Cultivation of malaria parasites 
 
The culture adapted CQS cloned D10 strain (derived from FCQ-27 from Papua New 
Guinea) (Ekong et al., 1993) was donated by Dr A.Cowman, Walter and Eliza Hall 
Institute of Medical Research, Melbourne, Australia.  The culture adapted CQR K1 
strain (isolated at Kanchnaburi, Thailand) (Thaithong et al., 1981) was donated by Dr 
D.Wallaker, University of Edinburgh, Edinburgh, Scotland.  
 
Continuous in vitro cultures of asexual erythrocyte stages of P. falciparum were 
maintained using a modified method of Trager and Jensen (1976). All procedures 














Transfusion Service, Groote Schuur Hospital, Cape Town, South Africa) was washed 
twice with wash medium and centrifuged at 1200 rpm for 5 minutes. The supernatant 
was aspirated off and the pellet containing mostly RBC’s was added to the parasites in 
the trophozoite stage. D-sorbitol was used to synchronise the parasites in the ring 
stage as the later stages incorporate more substances. The parasites were grown in 
tissue culture flasks (Greiner Bio-One) which were flushed with gas (3% O2, 4% CO2) 
for about 1 minute and incubated at 37ºC.  
 
After 24 hours the parasites were removed from the flask and centrifuged at 750 rcf 
for 3 minutes. The supernatant was removed and a thin blood smear was prepared 
from the pellet parasitized red blood cells (pRBC). The blood smear was fixed with 
methanol and stained with 10% Giemsa for microscopic evaluation. Complete 
medium (37ºC) was added to pRBC, which was gassed and incubated at 37ºC. 
Parasites were maintained at a parasitemia below 10%. 
 
7.6.3 Cryostorage and thawing of malaria parasites 
 
Parasites were frozen in sterile freezing medium prepared with 1.6 g sodium lactate, 
30 mg KCl, 1.38 g sodium dihydrogen phosphate, and 57 g glycerol in 100 ml 
Millipore water (mH2O). Glycerol forms a protective layer around the pRBC. 
Freezing medium was added to pRBC and transferred to cryotubes which were stored 
in liquid nitrogen. 
 
Parasites were thawed using three thawing solutions. Solution A contains 12% sodium 
chloride (NaCl), solution B contains 1.8% NaCl, and solution C contains 0.9% NaCl 
plus 0.2% glucose. Solutions A and B were added sequentially, centrifuged (400 rcf) 
for 5 minutes and the supernatant removed. Solution C was added to the pellet and 
allowed to stand for 5 minutes. This mixture was centrifuged and the pRBC was 


















7.6.4 Preparation of reagents for developing plates 
 
Malstat contains 400 µl Triton 100 which was heated gently to dissolve, 4 g L-lactate 
and 1.32 g Tris buffer in 200 ml of mH2O. This mixture was stirred to dissolve and 
allowed to cool. Then 22 mg of 3-acetyl pyridine adenine dinucleotide (APAD) was 
added and the pH adjusted to 9. Malstat is used to disrupt the red blood cell 
membrane thus exposing the parasite to nitro blue tetrazolium (Sigma). Nitro blue 
tetrazolium (NBT) solution consists of 160 mg NBT and 8mg phenazine ethosulphate 
in 100 ml of mH2O. All reagents were stored at 4°C. 
 
7.6.5 Antiplasmodial assay 
 
Quantitative assessment of anti-malarial activity in vitro was determined by a 
modified method described by Makler (1993). This method of detection has proven to 
be reliable (Basco et.al., 1995). This colorimetric enzymatic assay is based on LDH of 
the parasite being distinguishable from host LDH activity using APAD as an analogue 
of nicotinamide adenine dinucleotide (NAD). Lactate is converted to pyruvate by 
pLDH using APAD as a coenzyme. In the presence of reduced APADH the yellow 
coloured NBT is converted to a purple formazan salt. The percentage parasite survival 
will be determined measuring the conversion of NBT by P. falciparum.  Malstat is 
used to disrupt the red blood cell membranes thus exposing the parasite to NBT.  
 
7.6.6 Experimental set-up 
 
Dose response experiments: A 96 well microtitre plate (Greiner Bio-One) was used 
for this assay. Samples were tested in duplicate on at least two separate occasions. 
The final hematocrit and parasitemia was 1% for all experiments. The first row was 
used as a blank containing 100 µl of the hematocrit and 100 µl complete medium 
(CM). The second row was used as a positive control containing 100 µl of the 
parasitemia and 100 µl CM. The remaining rows contained 100 µl of various drug 
concentrations in CM and 100 µl parasitemia. The starting concentration of samples 
tested was 100 µg/ml, which were serially diluted with two-fold dilutions in CM to 














at an initial concentration of 100 ng/ml against the CQ sensitive strain and 1000 ng/ml 
against the CQ resistant strain of P. falciparum. The same dilution technique was used 
for all test samples. The microtitre plate was covered with a lid (Greiner Bio-One) and 
placed in a chamber.  The chamber was gassed for about 2 minutes and incubated for 
48 hours.  
 
Three-point concentration test: The same experimental conditions were applied as for 
dose response test (described above). The plate set-up was adjusted to three 
concentrations, instead of ten as for a full dose response experiment. The 
concentrations were selected based on previous activity. CQ was tested at 30 ng/ml, 
15 ng/ml and 7.5 ng/ml.  Samples were tested in duplicate in two or three independent 
experiments. 
 
7.6.7 Developing plates 
 
After 48 hours the plate was re-suspended and 15µl of the suspension was transferred 
to corresponding wells in another plate containing 100µl Malstat. Then 25µl of NBT 
was added to each well. Air bubbles are removed with a hair dryer. The NBT is light 
sensitive thus the plate is placed in a dark cupboard to develop. The plate was read 
using a micro plate reader to measure the absorbance at 620 nm.  
 
7.7 In vitro cytotoxicity testing 
 
7.7.1 Preparation of medium for cell culture 
 
Dulbecos Modified Eagles Medium (DMEM) (Highveld Biological, South Africa) 
consists of 13.53 g/L DMEM and 3.7 g/L NaHCO3 and pH 7.1. Nutrient mixture F-12 
HAM (HAMS) (Sigma) contains 10.7 g/L HAMS and 1.176 g/L NaHCO3 and the pH 
adjusted to 7.1. Foetal calf serum (Highveld Biological, South Africa) is heat 
inactivated and stored at -20ºC.  Cells were maintained in CM containing DMEM, 
HAMS and gentamycin (500 µl/L or 0.05 g/L) supplemented with 10% heat 














reagents underwent the same filtering technique as for parasite culturing reagents 
(8.5.1). Reagents and medium were stored at 4ºC.  
 
7.7.2 Sub culturing cells 
 
Cell culture was done under sterile conditions. The cells were maintained as 
monolayers in culture flasks (vented cap) (Greiner Bio-One) and incubated at 37ºC in 
a 5% CO2 humidified atmosphere. Once cells were confluent the medium was 
removed and the cells rinsed twice with 10ml of sterile phosphate buffer saline (PBS). 
Then 5 ml of 10% sterile trypsin (Highveld Biological, South Africa) was added. This 
procedure is done quickly as too long exposure to trypsin will denature the cell 
membrane. To inactivate the trypsin 5 ml CM was added. This cell suspension was 
centrifuged at 750 rpm for 5 minutes. The supernatant was poured off and the pellet 
was re-suspended in 5 ml CM. This cell mixture was used for the assay and freezing. 
Approximately 1 ml of the cell suspension was transferred to a new flask containing 
9ml of CM.  
 
7.7.3 Cryostorage and thawing of cells 
 
The freezing medium used contains 90% FCS and 10% DMSO. The cell suspension 
was mixed with freezing medium and stored in liquid nitrogen.  
 
Thawing medium consists of 30% FCS, 35% DMEM and 35% HAMS. The frozen 
cells were thawed and added to cold thawing medium. This mixture was centrifuged 
at 750 rpm for 5 minutes and the supernatant poured off. The pellet was re-suspended 
in thawing medium and transferred to a flask containing 9ml of thawing medium. The 
flask was incubated at 37ºC (5% CO2). 
 
7.7.4 Cytotoxicity assay 
 
The mammalian CHO cell line was used for cytotoxicity testing and was obtained 
















Cytotoxicity testing is important to establish whether the activity of the sample is 
selective to the test organism and not toxic to cells. This cell-line is easy to grow and 
widely used for cytotoxicity testing. The 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) assay was first described for use as a rapid 
colorimetric assay for cellular growth and survival, and compares well with other 
available assays (Mosmann et al., 1983 and Rubinstein et al., 1990). The tetrazolium 
salt MTT was used to measure growth and chemosensitivity. The tetrazolium ring is 
cleaved in active mitochondria thus only viable cells are able to reduce the water-
soluble yellow coloured MTT to water-insoluble purple coloured formazan (Sieuwerts 
et al., 1995).  
 
7.7.5 Experimental set-up 
 
Sample preparations were the same as for antiplasmodial screening (7.5). Each 
sample was tested in triplicate in two or three independent experiments. A 96 well 
microtitre plate (Greiner-Bio One) was used. The initial concentration of test samples 
was 100 µg/ml, which were serially diluted in complete medium with 10-fold 
dilutions to give 5/6 concentrations, the lowest being 0.001 µg/ml or 0.0001 µg/ml. 
Cells were sub cultured as previously described (7.7.2). A small aliquot of the cell 
suspension was mixed with 1% crystal violet for counting. The concentration of cells 
used was 105 cells/ml.  
 
Plating cells: Row H was used as a blank and contained 200 µl of CM. Rows G to A 
contained 100µl of CM and 100µl of the cell suspension. The plates were incubated 
for 24 hours.  
 
Addition of test samples: After 24 hours the medium was removed. Row G was used 
as a positive control which contained cells and CM. Row F to A contained dilutions of 
the test samples and cells. The final volume in each well was 200µl. The plate was 















7.7.6 Developing plates 
 
After 48 hours 25 µl of MTT was added to each well and incubated. After 4 hours the 
plate was centrifuged at 200 rpm for 10 minutes. The medium was removed and 100 
µl DMSO was added to dissolve the formazan crystals. The formazan product was 
determined using a microplate reader at 540nm wavelength.  
 
7.8 Data analysis for antiplasmodial and cytotoxicity assay 
 
Data was analysed in Microsoft Excel® 2002. The IC50-value is defined as the 
concentration inhibiting 50% of growth and was determined using a non-linear dose 
response curve fitting analysis in GraphPad Prism v.4.0. IC50-values are given as a 
mean value with standard deviations. 
 
7.9 In vitro antimycobacterial, antibacterial and antifungal testing 
 
Testing was performed by Tracy Seaman in the Division of Pharmacology (University 
of Cape Town). 
 
7.9.1 Antimycobacterial assay 
 
7.9.1.1 Broth micro dilution method 
 
M. aurum A+ was first isolated from human sputum (Tsukamura et al., 1966) and was 
obtained from the Pasteur Institute Culture collection (CIP). Middelbrook 7H9 broth 
(Becton Dickinson, Sparks, MD, USA) supplemented with 10% OADC (oleic acid, 
albumin, dextrose and catalase) (Remel, Lenexa, KS, USA) was used to grow M. 
aurum A+ (CIP 104482) from glycerol stocks stored at -70°C.  
 
Experimentation purposes: Middelbrook 7H9 broth was inoculated with a colony of 














well micro titre plates. The high-throughput screening of antimycobacterial agents in 
combination with the colorimetric method using tetrazolium salts was used (Chung et 
al., 1995 and Eloff et al., 1998).  
 
Each test sample was tested in triplicate. Row A was used as a blank which contained 
100 µl sterile distilled water (dH2O) and 100 µl 7H9 broth. Rows C – H were used to 
prepare 2-fold dilutions of the test sample in sterile dH2O to give ten concentrations. 
The culture was adjusted to an optical density of 0.125 at 550 nm to yield 
approximately 1x105 cfu/ml. Then 100 µl of this dilute culture was added to all wells 
except the blank row. To prevent dehydration the plates were loosely sealed in plastic 
bags and incubated (37°C) for 72 hours.  
 
Developing plates and data analysis: Growth was measured using p-
iodonitrotetrazolium salt (INT, Fluka) prepared to 0.4 mg/ml solution. INT changes 
colour to red in the presence of metabolising organism (Eloff et al., 1998). After 
incubation 40 µl of INT was added to the plates. Plates were incubated overnight at 
37°C. The lowest concentration with no indication of red as a result of INT was 
regarded as the MIC.  IC50-values were determined with a Modulus micro plate reader 
at 600 nm. Data was analysed in Microsoft Excel® 2002 and dose response curves 
were plotted using a non-linear dose response curve fitting analysis in GraphPad 
Prism v.4.0.  
 
7.9.1.2 BACTEC method 
 
Testing against M. tuberculosis was performed under biologically safe conditions 
according to the methodology described by Lall and Meyer (1999) for the 
antimycobacterial testing of crude plant extracts.  Susceptibility testing against M. 
tuberculosis H37Rv ATCC 25177 was performed using the radiometric BACTEC 460 
system (Becton Dickinson). This system monitors the production of radiolabelled CO2 
by the metabolizing organism which indicates the effect of the test sample on 















The BACTEC 12B vial used for this experiment contains radiolabelled 14Carbon 
substrate which is taken up by the test organism. A glycerol stock of M. tuberculosis 
stored at -70°C was used to inoculate BACTEC 12B vials. The vial was incubated at 
37°C until the Growth Index (GI) reading of 999 was reached. Then 100 µl of this 
culture suspension was used to inoculate a second BACTEC 12B vial which was 
incubated (37°C) until the GI reading was between 500 and 700.  
 
Experimental set-up: The BACTEC 12B vials were incubated at 37°C for all 
experimentation purposes. Test vials were inoculated with 100 µl of culture 
suspension from the second vial (GI = 500 – 700). Stock solutions of the test samples 
were prepared to 10.5 mg/ml in 50% methanol.  The test samples (100 µl) were added 
to the test vials in duplicate. A three-point concentration test at 62.5, 125 and 250 
µg/ml was performed.  A solvent control and an antibiotic, rifampicin (Sigma) at 2 
µg/ml were included in the experiment.  Two culture control vials were also included 
in the experiment.  A sample-free control vial was inoculated with 100 µl of the 
culture suspension (GI = 500 – 700).  Another sample-free control vial was inoculated 
with a 1:100 dilution of the organism in TB diluting fluid (NHLS Media department, 
Cape Town, South Africa). This control served as a representation of the bacterial 
population (1%) which is present in the test vials.  GI readings of the test vials were 
read daily and compared to the 1:100 dilution control vial. The experiment was 
stopped if the GI readings in the 1:100 dilution control vial had progressed to two 
readings over a GI of 30. 
 
Data analysis: The delta GI (∆GI) was defined as the difference in GI values of the 
last two days. The ∆GI values of the vials containing the test samples were 
determined. If the ∆GI value of the test sample is less than that of the 1:100 controls, 
the bacterial population was considered susceptible to the test sample at that 
concentration. The MIC of a sample is defined as the lowest concentration inhibiting 
more than 99% of bacterial growth. If inhibition is observed at 250 µg/ml but not at 

















7.9.2 Antibacterial and antifungal assay 
 
Stock cultures were obtained from the American Type Culture Collection (ATCC) of 
C. albicans ATCC 90028, S. aureus ATCC 12600 and K. pneumoniae ATCC 13883. 
The stock cultures were frozen by adding 20% sterile glycerol and storing at -70°C 
over long periods. Glycerol culture stocks which were used for experiments were 
stored at -20°C.  
 
For experimentation against the fungus, C. albicans, sabouraud dextrose agar (SDA, 
Merck) plate was inoculated with a single glycerol stock of the organism and 
incubated at 30°C for 48 hours. The plate was loosely sealed in a plastic bag to 
prevent dehydration. After incubation 5ml RPMI (BioWhittaker) at ph 7.0 was 
inoculated with a single colony and incubated further overnight. 
 
For experimentation against bacteria Gram positive Staphylococcus aureus and Gram 
negative K. pneumoniae tryptone soya agar (TSA, Oxoid) plates were inoculated with 
a single glycerol stock of either organism. Plates were loosely sealed in a plastic bag 
to prevent dehydration and allowed to grow overnight at 37°C. Then a single colony 
was used to inoculate 5 ml of tryptone soya broth (TSB, Oxoid) which was incubated 
at 37°C. 
 
Broth micro-dilution method for C. albicans: A modified colorimetric method 
described by Clancy and Nguyen (1997) and Pfaller and Barry (1994) was used to 
measure growth. Experiments were performed under sterile conditions in 96-well 
micro titre plates. The final concentration of RPMI in the wells was 1 x RPMI. Plates 
were loosely sealed in plastic bags to prevent dehydration when incubated. 
 
Experimental set-up: Test samples were prepared to 50 mg/ml in 100% MeOH and 
then diluted in sterile dH2O to a concentration of 1 mg/ml. A stock concentration of 
10µg/ml of ciprofloxacin (Sigma) was used as the bacterial reference drug control and 
25µg/ml of nystatin (Sigma) was used as the fungal reference drug control.   Each test 
sample was tested in duplicate in two separate assays (total replicates = 4). Row A 














RPMI was substituted with TSB for bacteria. Rows C – H were used to prepare 2-fold 
dilutions of the test sample in sterile dH2O to give concentrations ranging from 0.97 – 
250µg/ml.  
 
Fungi: The overnight culture was diluted (1:50) in RPMI and 50 µl of mixture was 
added to all wells except the blank row to yield approximately 1 x 105 cfu/well. Plates 
were incubated at 30°C for 48 hours.  
 
Bacteria: The overnight culture was diluted (1:200) in TSB and 50 µl of mixture was 
added to all wells except the blank row to yield approximately 1 x 105 cfu/well. Plates 
were incubated overnight at 37°C.     
Developing plates: After incubation 40 µl of INT (0.4 mg/ml) was added to the plates. 
Plates were incubated at 30°C for 6 – 8 hours when tested against fungi and 
developed for 3 – 4 hours at either 37°C or room temperature when tested against 
bacteria. The lowest concentration with no indication of red as a result of INT was 
regarded as the MIC.   
 
7.10 In vivo antiplasmodial testing 
 
7.10.1 Test animals  
 
The animals used were wild strains of C57 BL6 mice (7-10 weeks old) which were 
obtained from the animal unit at the University of Cape Town (South Africa). This 
study was approved by the Animal Research Ethics Committee (University of Cape 
Town). Animal handling complied with guidelines followed by the University of 
Cape Town which were adapted from the South African Medical Research Council 
(MRC, 2004). The animals were housed in standard cages at room temperature 




















The cryopreserved CQR Plasmodium yeolii NS strain originated from the Institute for 
Evolutionary Biology, Edinburgh, Scotland, United Kingdom. The cryopreserved 
CQS Plasmodium berghei ANKA strain originated from the Swiss Tropical Institute, 
Basel, Switzerland. Stocks were kept in liquid nitrogen at -80°C. The cryopreserved 
parasite stocks were thawed and two mice were interperitoneally infected. The 
parasitemia was allowed to develop over 5 days.  Blood was collected by an incision 
at the tail vein and the parasitemia was determined microscopically using 10% giemsa 
stained thin blood smears. The cells/ml was determined using a hemacytometer and 
diluted with phosphate buffered saline (PBS) to a suspension of 5 x 106 parasitized 
cells/ml. The animals were infected with 0.2 ml of 1 x 106 parasitized cells/ml 
solution. Percentage growth inhibition was determined as follows: 
 
% Growth inhibition = parasitemia of control – parasitemia of test sample    x 100 
                   parasitemia of control 
 
7.10.3 Dose preparation 
 
CQ was used as the reference drug in all experiments and was prepared to 15 mg/kg 
bw in Millipore water. Plant extracts were prepared to 400 mg/kg bw or 800 mg/kg 
bw in 5% sodium bicarbonate (with or without 5% ethanol) or a lipid-based 
formulation. Compound 3 was tested at 100 mg/kg bw and was dissolved in 10% 
DMSO. Test samples were administered as a suspension if not completely dissolved. 
Solvent concentrations for 10% DMSO, 5% sodium bicarbonate and the lipid-based 
formulation have proven to be safe in vivo (Peters et al., 2002 and Wu et al., 2006). 
Controls for dose preparations were performed using the 4-day suppressive test (Fig 
16).  The CQ control group and all test groups except the control were treated daily. 
The route of administration was by gavage for all experiments. The mice received 200 
µl of the test suspensions except for the SMEDDS formulation volumes which varied 
depending on the dose and body weight. The mice were monitored daily and the 















7.10.3 Schizontocidal activity 
 
7.10.3.1 Four-day suppressive test 
 
The mice were tail-bled on days 3, 4 and 7 post infection to determine the parasitemia 
using thin blood smears. The 4-day suppressive test was followed for this experiment 
similar to the test described by Peters et al. (1993).  Treatment was started 24 hours 
post infection. The positive control group did not receive treatment during the study. 
Parasitemia is given as a mean value with standard deviations.  The mice were 
sacrificed 7-9 days post infection. 
 
7.10.3.2 Seven-day suppressive test 
 
The mice were tail-bled on days 4 and 7 post infection to determine the parasitemia 
using thin blood smears. Mice were grouped into 4 groups with 2 groups of 5 mice for 
the test samples and 2 groups of 3 mice for the controls (CQ and positive). Treatment 
was started 24 hours post infection. The positive control group did not receive 
treatment during the study. Parasitemia is given as a mean value with standard 
deviations.  The mice were sacrificed 9-10 days post infection. 
 
7.10.4 Parasite clearance experiment 
 
The clearance experiment was performed according to a modified method described 
by Hou et al. (2004). Mice were grouped into 4 groups with 2 groups of 5 mice for the 
test samples and 2 groups of 4 mice for the controls (CQ and positive).  Parasitemia 
was allowed to develop to 5 – 10% before commencing treatment. The crude extract 
was administered orally at two different doses for 4 consecutive days. The positive 
control group did not receive treatment during the study. The mice were tail-bled on 
days 4, 7 and 8 post infection to determine the parasitemia using thin blood smears. 
Parasitemia is given as a mean value with standard deviations.  The mice were 
















7.10.5 Prophylactic experiment 
 
The prophylactic experiment was performed according to a modified method 
described by Rane et al. (1979). Treatment was started four days prior to infection for 
4 consecutive days. The treatment was stopped on day 0 (day of infection). The 
parasitemia was monitored from day 4 post infection.  Mice were grouped into 4 
groups with 2 groups of 5 mice for the test samples and 2 groups of 4 mice for the 
controls (CQ and positive). The positive control group did not receive treatment 
during the study. Parasitemia is given as a mean value with standard deviations.  The 
mice were sacrificed 8-9 days post infection. 
  
7.11 Preliminary pharmacokinetic study of S. aethiopicus using LC-
MS/MS technology 
 
7.11.1 Test animals 
 
Animal handling and conditions were the same as described previously (7.10.1). One 
batch of 10 mice was used for all experiments. A washout period of 2-3 weeks was 
allowed between experiments. O+ human blood (Western Province Blood Transfusion 
Service, Groote Schuur Hospital, Cape Town, South Africa) was used for the 
preparation of standard controls. The routes of administration used were oral (gavage) 
or subcutaneous. A volume of 200 µl was given to mice except for the oil-based 
formulation which varied according to weight.  
 
7.11.2 Method development for bioavailability study of compound 3 
 
7.11.2.1 Mass spectrometry and chromatography conditions 
 
An Applied Biosystems 3200 Q-trap mass spectrometer coupled to a high 
performance liquid chromatography system was used to analyse the samples.  A 
Phenomenex C18 (15 cm x 4.6 mm, 5 µm) column with an injection volume of 5 µl 














isocratically for 1.5 min. Stock solutions of compound 3 were prepared to 10 µg/ml in 
whole blood. 
 
7.11.2.2 Sample preparation 
 
Liquid-liquid extraction of compound 3: 10 µl of spiked whole blood (10 µg/ml) was 
added to 50 µl of the respective pH buffers. An organic solvent, ethyl acetate (5 x 
volume of pH buffer, 250 µl) was added. EA was selected as it was used for 
extraction of plant material. This mixture was vortexed for 1 minute, centrifuged at 13 
000 rcf (5 min) and 200 µl of the supernatant removed. The supernatant was dried in 
MS-inserts using a cold trap system and reconstituted in 100 µl MP. This mixture was 
vortexed for 15 seconds and injected onto the LC-MS/MS for analysis.  
 
Extraction of compound 3 in different matrixes: Approximately 1 ml of whole blood 
was separated into a RBC pellet and plasma by centrifugation (13 000 rcf for 5 min). 
Then 30 µl of plasma or RBC’s were added to 150 µl pH 10 buffer. EA (750 µl) was 
added to the mixture, vortexed for 1 min and centrifuged. The supernatant was 
removed, dried in MS-inserts using a cold trap system and reconstituted in 100 µl MP 
for analysis. The percentage recovery was determined as a mean value (standard 
deviation): 
 
% Recovery = peak area of sample / peak area of standard control x 100 
 
7.11.3 Bioavailability study of compound 3 
 
7.11.3.1 Mass spectrometry conditions 
 
An Applied Biosystems 3200 Q-trap mass spectrometer coupled to a high 
performance liquid chromatography system using a Phenomenex C18 (15 cm x 4.6 
mm, 5 µm) column with an injection volume of 5 µl. The MP was acetonitrile 
















7.11.3.2 Sample preparation and extraction process 
 
Standards of compound 3 were prepared to a stock solution of 1 µg/ml in MP.  Stock 
solutions were serially diluted two-fold from 10 µg/ml to 0.15 µg/ml in plasma. 
Samples were stored at -20°C over short periods and at -80°C for long term storage. 
 
Blood sampling and extraction of test samples: Blood was collected by an incision at 
the tail vein or the tip of tail, in heparin-coated eppendorfs and immediately placed on 
ice. Approximately 40 µl of blood was collected at 5 time intervals (Table 15). Blood 
samples were centrifuged at 13 000 rcf for 5 min and 10 µl of plasma removed. The 
plasma was added to 50 µl pH buffer and extracted immediately. 250 µl of EA was 
added to plasma and pH buffer mixture. This was vortexed for 1 min, centrifuged for 
5 min at 13 000 rcf and 200 µl of the supernatant removed. The supernatant was dried 
in LCMS inserts using a cold trap system. The dried material was reconstituted the 
following day in 100 µl of MP for analysis.  
 
7.11.4 Bioavailability study of crude extract 
 
Experimental conditions were as described in 7.11.3.1.  Standards of compound 1, 2 
and 3 were prepared to a stock solution of 1 µg/ml in MP.  Stock solutions were 
serially diluted two-fold from 10 µg/ml to 0.15 µg/ml in plasma. Samples were stored 
at -20°C over short periods and at -80°C for long term storage. 
 
7.11.4.1 Sample preparation and extraction process 
 
Standards of compound 3 were prepared to a stock solution of 1 µg/ml in MP.  Stock 
solutions were serially diluted two-fold from 10 µg/ml to 0.15 µg/ml in plasma. 



















7.11.5 Metabolite study of compound 3 
 
7.11.5.1 Mass spectrometry and chromatography conditions 
 
An Applied Biosystems 3200 Q-trap mass spectrometer coupled to a high 
performance liquid chromatography system using a Phenomenex C18 (15 cm x 4.6 
mm, 5 µm) column with an injection volume of 5 µl. The MP was ACN:0.1% formic 
acid (6:4) and an isocratic run rate of 15 min. The molecular ion of compound 3 (m/z 
244) and the major product ion of m/z 116 was selected. For the precursor experiment 
the LC-MS/MS the molecular ion was first isolated on the basis of its mass/charge 
ratio and then passed into the collision cell. The collision cell is then filled with an 
inert gas such as helium and a potential difference is applied.  Product ions are formed 
when the energized ions collide with the gas molecules which move out of the 
collision cell and hit the detector. Product ions of unknown metabolites should 
correspond to the product ions of the parent compound.   
 
7.11.5.2 Sample preparation 
 
Samples were collected over a period of two hours. Samples were pooled and 
extracted immediately after collection. 
 
Blood sampling: Approximately 10 – 20 µl of blood was collected at various time 
intervals. 30 µl of whole blood was extracted with ACN, vortexed for 2 min and 
centrifuged. The supernatant was injected onto the LC-MS/MS. 
 
Urine samples: Mice normally urinate by reflex when handled thus no added stress 
was placed on the animal to provoke urination. Approximately 10 µl of urine was 
collected at the same time as blood collections except for the collection after 1 hour 
which yielded too little material. The urine samples were pooled after collection and 
diluted in MP (1:50) for analysis.  
 
Faeces samples: The cage of the test animal was cleaned 24 hours before the 














experiment before dosing which served as the blank control. Droppings were 
collected again 24 hours after the experiment. Both samples were extracted with 100 
ml of ACN. This mixture was stirred for 30 min, centrifuged for 5 min at 10 000 rcf 
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Figure 54 Pooled dose-response curves compounds isolated from S. aethiopicus 
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Figure 55 Pooled dose-response curves of crude EA extract and compounds isolated 
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Figure 56 Pooled dose-response curves of SPE fractions from S. aethiopicus against 
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Figure 57 Dose-response curve of liquid-liquid fraction (pH 11) from S. aethiopicus 
extract against M. aurum A+  
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Figure 58 Pooled dose-response curves of A. ferox crude extract against the CHO cell-
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Figure 59 Pooled dose-response curves of A. ferox against CQS D10 strain and CQR 






























































Figure 60 Pooled dose-response curves of chloroquine against the CQS D10 strain 
and CQR K1 strain of P. falciparum (n = 2) 
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Figure 62 Pooled dose-response curves of A. ferox DCM extract (n = 2) collected in 
summer and chloroquine control (n = 3) against CQR K1 strain of P. falciparum  
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Figure 63 Pooled dose-response curves of SPE fractions (20% ACN increments) 
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Figure 64 Pooled dose-response curves of SPE fractions (5% ACN increments) from 
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Figure 65 (Continued) Pooled dose-response curves of SPE fractions (5% increments) 
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Figure 66 Pooled dose-response curves of chromatotron fractions obtained from 90% 





















IC50 = 3.581 礸/ml






















IC50 = 1.030 礸/ml























IC50 = 15.488 礸/ml






















IC50 = 6.026 礸/ml























IC50 = 9.683 礸/ml























IC50 = 12.764 礸/ml















Figure 67 Pooled dose-response curves of chromatotron fractions obtained from 85% 
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Figure 68 Pooled dose-response curves of chromatotron fractions obtained from 80% 
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Figure 69 Pooled dose-response curves of chromatotron fractions obtained from 60% 
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Figure 70 Pooled dose-response curves of TLC bands from chromatotron band D, 
90% SPE ACN fraction against the CQS D10 strain of P. falciparum (n = 2) 
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Figure 71 Pooled dose-response curves of TLC bands from chromatotron band A, 
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Figure 72 Pooled dose-response curves of A. ferox extracts separated via TLC tested 
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A.ferox outer leaf extract: TLC band 7
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Figure 73 (Continued) Pooled dose-response curves of A. ferox extracts separated via 
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Figure 74 Pooled dose-response curves of compounds isolated from A. ferox against 
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Figure 75 Pooled dose-response curves of compounds isolated from A. ferox against 
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Figure 76 Pooled dose-response curves of Aloe-emodin and chloroquine against the 
CQS D10 strain of P. falciparum (n = 3) 
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Figure 77 A. ferox: Averaged weights of mice using the four-day suppressive test 





























































































































































































































































































































































































































































































Figure 81 1H spectrum of compound 1 
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Standard curves of compound 3 isolated from S. aethiopicus 
 
20032007.rdb (Compound 3): "Quadratic" Regression ("1 / x" weighting): y = -165 x^2 + 2.11e+004 x + 268 (r = 0.9999)
































Figure 99 Standard curve for optimisation experiment: pH extractions 
 
10042007plasma extraction.rdb (Compound 3): "Quadratic" Regression ("1 / x" weighting): y = -246 x^2 + 1.75e+004 x + -365 (r = 0.9978)









































16052007.rdb (Compound 3): "Quadratic" Regression ("1 / x" weighting): y = 784 x^2 + 7.36e+004 x + -1.19e+003 (r = 0.9990)





























Figure 101 Standard curve for comparative experiment: Oral vs. SC administration of 
compound 3 in 10% DMSO 
 
20062007.rdb (Compound 3): "Quadratic" Regression ("1 / x" weighting): y = 1.84e+003 x^2 + 1.45e+005 x + -8.64e+003 (r = 0.9991)






























Figure 102 Standard curve for comparative experiment: Oral vs. SC administration of 













06082007.rdb (Compound 3): "Quadratic" Regression ("1 / x" weighting): y = 658 x^2 + 1.1e+005 x + 2e+004 (r = 0.9932)



































Figure 103 Standard curve for administration of the EA extract of S. aethiopicus 
experiment 
  
 
 
 
 
 
 
